NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
1 
  
NCI Protocol #:  [ZIP_CODE]  
Local Protocol #:  NCI10136  
 
ClinicalTrials.gov Identifier :  TBD  
 
TITLE:   A PHASE 2 STUDY OF AZD1775, A WEE1 INHIBITOR, IN PATIENTS 
WITH CCNE1 AMPLIFICATION  
 
Corresponding Organization : LAO -TX035 / University of [LOCATION_007] MD Anderson Cancer Center 
LAO   
 
 
Principal Investigator:  [INVESTIGATOR_798153], MD, PhD  
University of [LOCATION_007] MD Anderson Cancer Center  
[ADDRESS_1100811] Office: 713 -792-4318  
Fax: [PHONE_16647]  
[EMAIL_15195]  
 
Participating O rganizations  (Only the participating LAOs should be listed. ) 
LAO -[ZIP_CODE]  / University Health Network Princess Margaret Cancer Center LAO  
LAO -CA043 / City of Hope Comprehensive Cancer Center LAO  
LAO -CT018  / Yale University Cancer Center LAO  
LAO -MA036 / Dana -Farber - Harvard Cancer Center LAO  
LAO -MD017 / JHU Sidney Kimmel Comprehensive Cancer Center LAO  
LAO -MN026 / Mayo Clinic Cancer Center LAO  
LAO -NC010 / Duke University - Duke Cancer Institute LAO  
LAO -NJ066 / Rutgers University - Cancer Institute of New Jersey LAO  
LAO -OH007 / Ohio State University Comprehensive  Cancer Center LAO  
LAO -PA015 / University of Pi[INVESTIGATOR_25449] -TX035 / University of [LOCATION_007] MD Anderson Cancer Center LAO  
LAO -NCI / National Cancer Institute LAO  
 
 
 
 
 
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
2 
 Statistician:     Study Regulatory Coordinator:  
Kenneth  Hess,  PhD   
 Katherine Torres, MHA  
[ADDRESS_1100812].,  Unit 455  
Houston,  [LOCATION_007]  [ZIP_CODE]  Houston,  [LOCATION_007]  [ZIP_CODE]  
[PHONE_16648]  [PHONE_16649]  
[EMAIL_5970]   Ktorres4 @mdanderson.org  
 
Responsible Research Nurse:          Responsible Data Manager:  
Valerie Marcott, RN  Naiyi Shi , MS  
[ADDRESS_1100813].,  Unit 455  
Houston,  [LOCATION_007]  [ZIP_CODE]  Houston,  [LOCATION_007]  [ZIP_CODE]  
[PHONE_16650]  [PHONE_16651]  
[EMAIL_15196]  [EMAIL_15197]  
 
Translational Investigators:        
Khandan Keyomarsi, PhD  Funda Meric -Bernstam, MD  
[ADDRESS_1100814].,  Unit 455  
Houston,  [LOCATION_007]  [ZIP_CODE]  Houston,  [LOCATION_007]  [ZIP_CODE]  
[PHONE_16652]  [PHONE_16653]  
kkeyomar @mdanderson.org  fmeric @mdanderson.org  
 
 
 
NCI-Supplied Agent(s):  AZD1775 ( Adavosertib ) NSC  751084 , [COMPANY_008] Pharmaceuticals  
IND # :  
IND Sponsor:  DCTD,  NCI 
 
 
Protocol Type / Version # / Version Date:      Original/ version date: 06/24/2017  
                                                                             Revision/version date: 09/14/2017  
Revision/version date: 10/12/2017    
Revision/version date: 11/20/2017   
Revision/version date: 02/01 /2018  
Revision/version date: 03/02/2018  
Revisi on/version date: 03/30/2018  
Revision/version date:  04/26/2018  
Revision/version date: 06/12/2018  
Revision/version date: 07/05/2018  
Revision/version date: 07/18/2018  
Revision/version date: 08/17/2018  
Revision/version date: 01/22/ 2019  
Revision/version date: 06/21/2019  
Revision/version date: 08/21/2019  
Revision/version date: 06/02/2020
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100815] version 1.1, and toxicity profile according to 
NCI-CTCAE 5.0.  
 
The primary endpoint is the objective response rate, and the secondary endpoints are safety, 
tolerability, and survivals. As  shown in Figure 1, patients will be treated with AZD1 775 at 300 
mg PO daily for 5 days each week for 2 weeks (one cycle of therapy is 21 days) . Blood and 
tumor specimens will be collected for translational research.  
 
 
Figure 1. Study Schema  
  

NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
4 
 TABLE OF CONTENTS  
 
TITLE:  A Phase 2 Study of AZD1775, A Wee1 Inhibitor, in Patients with CCNE1 
Amplification  ................................ ................................ ................................ ................................ .1 
SCHEMA  ................................ ................................ ................................ ................................ ......... 3 
TABLE OF CONTENTS  ................................ ................................ ................................ ................. 4 
1. OBJECTIVES  ................................ ................................ ................................ ...................... 7 
1.1 Primary Objectives  ................................ ................................ ................................ ...7 
1.2 Secondary Objectives  ................................ ................................ ............................... 7 
2. BACKGROUND  ................................ ................................ ................................ ................. 8 
2.1 Study Disease(s) ................................ ................................ ................................ .......8 
2.2 AZD1775: an oral, potent Wee1 inhibitor  ................................ ............................... 9 
2.3 Clinical experience with AZD1775  ................................ ................................ .......10 
2.4 AZD1775 Pharmacokinetics  ................................ ................................ .................. 13 
2.5 AZD1775 Safety  ................................ ................................ ................................ ....15 
2.6 Cyclin E encoded by [CONTACT_798190]1 is a critical G1/S transition regulator  ..................... [ADDRESS_1100816] a P hase II Basket Study in CCNE1 Amplified 
Solid Tumors  ................................ ................................ ................................ .......... 21 
2.9 Correlative Studies – Background and Rationale  ................................ .................. 24 
3.   PATIENT SELECTION  ................................ ................................ ................................ .......... 28 
3.1 Patient Inclusion Criteria  ................................ ................................ ....................... 28 
3.2 Patient Exclusion Criteria  ................................ ................................ ...................... 30 
3.3 Inclusion of Women and Minorities  ................................ ................................ ......32 
4.   REGISTRATION PROCEDURES  ................................ ................................ ......................... 33 
4.1 Investigator and Research Associate Registration with CTEP  .............................. 33 
4.2 Site Registration  ................................ ................................ ................................ .....34 
4.3 Patient Registration  ................................ ................................ ................................ 36 
4.4 General Guidelines  ................................ ................................ ................................ .37 
5. TREATMENT PLAN  ................................ ................................ ................................ ........ 38 
5.1 Agent Admini stration ................................ ................................ ................................ ...38 
5.2 Study Procedures  ................................ ................................ ................................ ......... 38 
5.3 General Concomitant Medication and Supportive Care Guidelines  ............................ 41 
5.4 Restrictions during the study  ................................ ................................ ....................... 42 
5.5 Duration of Therapy  ................................ ................................ ................................ .....44 
5.6 Duration of Follow Up  ................................ ................................ ................................ .46 
5.7 Criteria for Removal from Study  ................................ ................................ ................. 47 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
5 
 6. DOSING DELAYS/DOSE MODIFICATIONS  The principal investigator [INVESTIGATOR_798154].  .......48 
6.1  Definition of  adverse events  ................................ ................................ ....................... 48 
6.2 Definitions of serious adverse event  ................................ ................................ ......48 
6.3 Dose Modification  ................................ ................................ ................................ .49 
6.4 Dose mod ifications due to hematologic toxicity  ................................ ................... 50 
6.5 Dose modifications due to non -hematologic toxicity  ................................ ............ 51 
6.6 Recording of adverse events  ................................ ................................ .................. 54 
7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  ............................ [ADDRESS_1100817] (CAEPRs)  ................... 60 
7.1.1  CAEPR for AZD1775  ................................ ................................ ............................ 60 
7.2 Adverse Event Characteristics  ................................ ................................ ............... 63 
7.3 Expedited Adverse Event Reporting  ................................ ................................ ......65 
7.4 Routine Adverse Event Reporting  ................................ ................................ ......... 67 
7.5 Secondary Malignancy  ................................ ................................ ........................... 67 
7.6 Second Malignancy  ................................ ................................ ................................ 67 
8. PHARMACEU TICAL INFORMATION  ................................ ................................ .......... 68 
8.1 AZD1775 (NSC #751084)  ................................ ................................ ..................... [ADDRESS_1100818] ................................ ................................ ........................ 76 
11.1  Definitions ................................ ................................ ................................ .............. 77 
11.2  Disease Parameters  ................................ ................................ ................................ 77 
11.3  Metho ds for Evaluation of Measurable Disease  ................................ .................... 79 
11.4  Response Criteria  ................................ ................................ ................................ ...82 
12. STUDY OVERSIGHT AND DATA REPORTING / REGULATORY 
REQUIREMENTS  ................................ ................................ ................................ ....................... 85 
12.1  Study Oversight  ................................ ................................ ................................ .....85 
12.2  Data Reporting  ................................ ................................ ................................ .......86 
12.3  CTEP Multicenter Guidelines  ................................ ................................ ................ 87 
12.4  Collaborative Agreements Language  ................................ ................................ .....87 
12.5  Genomic Data Sharing Plan  ................................ ................................ ................... 89 
12.6  Safety Monitoring  ................................ ................................ ................................ ..90 
12.7  Data Safety Monitoring Plan  ................................ ................................ ................. 90 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
6 
 13 STATISTICAL CONSIDERATIONS ................................ ................................ ............... 91 
13.1  Study Design/Endpoints ................................ ................................ ......................... 91 
13.2  Sample Size/Accrual Rate  ................................ ................................ ...................... 92 
13.3  Stratification Factors  ................................ ................................ .............................. 92 
13.4  Analysis of Secondary Endpoints  ................................ ................................ .......... 92 
13.5  Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ .......94 
REFERENCES  ................................ ................................ ................................ .............................. 95 
APPENDIX A: PERFORMANCE STATUS CRITERIA  ................................ ............................. 98 
APPENDIX B: PATIENT DRUG INFORMATION HANDOUT AND WALLET CARD  ........ 99 
APPENDIX C: MEDICATION DIARY  ................................ ................................ ..................... 101 
TABLE OF  CONTENTS  ................................ ................................ ................................ ............. 105 
1.0 PURPOSE  ................................ ................................ ................................ ............ 106 
2.0 SCOPE  ................................ ................................ ................................ ................. 106 
3.0 ABBREVIATIONS  ................................ ................................ ............................. 106 
4.0 INTRODUCTION  ................................ ................................ ............................... 106 
5.0 ROLES AND  RESPONSIBILITIES  ................................ ................................ ...106 
6.0 MATERIALS AND EQUIPMENT REQUIRED  ................................ ................ 107 
7.0 OPERATING PROCEDURES  ................................ ................................ ............ 108 
7.4 Tumor Needle Biopsy Collection and  Handling  ................................ .................. 108 
8.0 SHIP TO FNLCR FOR ANALYSIS  (OPTIONAL)  ................................ ........... 110 
8.6 Day of  Shipment  ................................ ................................ ................................ ..110 
APPENDIX 1: BATCH  RECORD  ................................ ................................ .............................. 112 
APPENDIX 2: PD SAMPLE SHIPPI[INVESTIGATOR_798155]  ................................ ............................... 114 
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
7 
 1. OBJECTIVES  
 
1.1   Primary Objectives  
•   To evaluate the proportion of patients with the objective response rate (ORR) to AZD1775 in 
patients with advanced refractory cancers with CCNE1 amplification.   
 
 
1.2   Secondary Objectives  
 
•   To evaluate the proportion of patients alive and progression free at 6 months of treatment with 
AZD1775 in patients with advanced refractory cancers with CCNE1 amplification.   
 
•   To evaluate proportion of patients with extended time to progression (time t o progression on 
AZD1775/ time to progression on last line of therapy ≥ 1.3) . 
 
•   To evaluate time until death or disease progression.  
 
•   To identify potential predictive biomarkers beyond the genomic alteration by [CONTACT_798191], RNA, protein and imaging -based 
assessment platforms.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
8 
 2. BACKGROUND  
2.1   Study Disease(s)  
 
The study diseases include all  histologically advanced solid tumors  harboring CCNE1 
amplification . 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
9 
 2.2   AZD1775: an oral, potent Wee1 inhibitor  
 
AZD1775 is a potent, highly selective, ATP -competitive, small -molecule inhibitor of Wee1 
kinase, displaying in vitro  and in vivo  preferential sensitization of tumor cells (relative to normal 
cells) to various DNA -damaging anticancer agents and modalities while sparing normal tissues 
from radiation - and chemotherapy -induced toxicity [1, 2] . Wee1 phosphorylates and inhibits 
cyclin-dependent kinases 1 (CDK1) and 2 (CDK2), and is involved in regulation of the intra -S 
and G2 cell cycle checkpoints [3]. Proper functioning of these checkpoints is  essential for the 
DNA metabolism and the DNA damage response.  The gene expression profile induced by [CONTACT_90337]1 
inhibition revealed dose -dependent inhibition of direct substrate pCDK1 and changes of genes 
regulating S -G2 cell cycle progression or checkpoints, w hich are consistent with the mode of 
action of Wee1 inhibitors [4]. Inhibition of WEE1 is expected to release a tumor cell from DNA 
damage -induced arrest at the G2/M boundary, so that un -repaired DNA damage may be taken 
into mitosis (M -phase). Since cancer  cells exhibit higher levels of endogenous damage than 
normal cells, as well as exhibiting loss of one or more DNA damage response capabilities, this is 
expected to preferentially enhance cancer cell death through mitotic catastrophe compared to 
normal cel ls. Also, inhibition of WEE1 is expected to cause aberrantly high CDK2 activity in S -
phase cells that will have multiple effects  for cancer cells that already have G1/S checkpoint 
aberrations. These include de -regulated replication origin firing before suf ficient 
deoxynucleotides are available, resulting in a higher degree of replication stress and ultimately 
replication fork collapse where endonucleases generate DNA damage, which leads to apoptosis.  
 
CDK1 (also called cell division cycle 2, or CDC2) activi ty drives a cell from the G2 phase of  the 
cell cycle into mitosis. In response to DNA damage, WEE1 inhibits CDK1 to prevent the  cell 
from dividing until the damaged DNA is repaired (G2 checkpoint arrest).  Inhibition of  WEE1 is 
expected to release a tumor c ell from DNA damage -induced arrest at the G2/M  boundary, so that 
un-repaired DNA damage may be taken into mitosis (M -phase). Since  cancer cells exhibit higher 
levels of endogenous damage than normal cells, as well as  exhibiting loss of one or more DNA 
dama ge response (DDR) capabilities, this is expected to  preferentially enhance cancer cell death 
through mitotic catastrophe compared to normal cells.  In vitro experiments demonstrate that 
AZD1775 has synergistic cytotoxic effects when  administered in combinat ion with various DNA 
damaging agents that have divergent  mechanisms of action. Therefore, the clinical development 
of AZD1775 includes its use as a  chemosensiti zing drug in combination with a cytotoxic agent 
(or combination of agents) for  treatment of adva nced solid tumors.  
 
CDK2 activity drives a cell into, and through  the DNA synthesis  (S-phase ) of the cell cycle in 
which the genome is  duplicated in preparation for cell division.  An important aspect of CDK2  
regulation of replication is the control of replication origin firing. WEE1, under normal  
circumstances, regulates CDK2 to provide sufficient time to generate the optimum  environment 
for DNA synthesis, such as the generation of a sufficient pool of  deoxynucleotide triphosphates 
(dNTPs), the building  blocks of DNA . Inhibition of WEE1 is expected to cause aberrantly  high 
CDK2 activity in S -phase cells  that will have  multiple consequences for cancer cells that already 
have G1/S checkpoint aberrations such as  p53 mutations or CDKN2A deletions [5]. These 
include de -regulated replication  origin firing before sufficient dNTP s are available, resulting in a 
higher degree of replication  stress (already greater in cancer cells). The resulting increase in 
levels of replication stress will  result in replication fork stalling, the generation of unstable DNA 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100819] 
significantly higher levels  of replication stress.   
 
In sarcoma cell lines, AZD1775 treatment at clinically relevant concentrations led to unchecked 
entry into mitosis associated with increased phosphorylated CDK1Tyr-15 and histone 3 (pH3Ser-10); 
DNA damage associated with phosphorylated -H2AXSer-139; and initiation of apoptosis 
associated with cleaved caspase -3 [6]. Clonogenic survival and tumor xenograft analyses showed 
that AZD1775 abrogated radiation -induced G 2 blockade by [CONTACT_798192] -induced DNA lesions into premature mitosis and inducing apoptosis i n p53 -
defective tumor cells but not in p53 -wt cell lines [7]. AZD1775 selectively sensitizes p53 -
deficient tumor cells to DNA -damaging agents such as gemci tabine, carboplatin, cisplatin, 
pemetrexed, doxorubicin, camptothecin, mitomycin C, and 5 -fluorouracil [8-11]. Further 
investigation showed that AZD1775 displayed single -agent activity and enhanced the response 
of HPV -positive HNSCC to cisplatin both in vitro  and in vivo , which was associated with G2 
checkpoint abrogation, persistent DNA damage, and apoptosis ind uction through decreased 
expression of the anti -apoptotic proteins MCL -1 and XIAP [12]. The therapeutic effects of 
AZD1775 as single agent or comb ination with other agents are actively being evaluated in more 
than 30 clinical trials across multiple tumor types. A phase I study of 25 patients with a 
refractory solid tumor showed that single -agent AZD1775 can be safely administered as 225 mg 
twice per  day orally over 2.5 days per week for 2 weeks every 21 days, and confirmed partial 
responses were observed in two patients carrying a BRCA  mutation (one with head and neck 
cancer and one with ovarian cancer), providing preliminary clinical evidence of its  preferential 
cytotoxicity to DNA damage repair –deficient cancer cells [13].  
 
In vitro experiments demonstrated that AZD1775 inhibits WEE1 activity and induces DNA 
damage as well as G2/M checkpoint escape. AZD1775 sensitizes tumor cells to cytotoxic effects 
of different DNA damaging agents, including chemotherapi[INVESTIGATOR_014]. In mouse and rat xenograf t 
models, anti -tumor efficacy of chemotherapy was significantly enhanced by [CONTACT_99213]1775.  
Treatment with AZD1775 in nude mouse xenograft models resulted in significant tumor growth 
inhibition at tolerated doses, and also enhanced the anti -tumor growth effect o f gemcitabine, 
carboplatin, radiation therapy, and olaparib, a PARP inhibitor that also induces replication 
associated DNA damage.  Moreover, in preclinical cancer cell models associated with high levels 
of endogenous replication stress resulting from a com bination of G1/S checkpoint deficiencies 
due to p53 mutations or CDKN2A deletions and the over -expression of oncogenic drivers such 
as MYC, mutant KRAS or the amplification of Cyclin E, AZD1775 also demonstrated 
significant single -agent anti -tumor activity . 
 
2.[ADDRESS_1100820] been exposed to AZD 1775 in [COMPANY_008] -sponsored or [COMPANY_006] -sponsored clinical 
studies.  Of these 551 patients, 103 received AZD1775 monotherapy, 407 patients received 
AZD1775 in combination with cytotoxic chemotherapy agents and the remaining 41 patients 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100821] received single doses per cycle as high as 1300 mg of AZD1775 as 
monotherapy, 325  mg of AZD1775 in a single -dose in combination with chemotherapy, and 325 
mg twice a day (BID) i n a multiple -dose regimen in combination with chemotherapy.  In 
addition, approximately [ADDRESS_1100822] also received AZD1775 as part of externally -
sponsored scientific research.   
 
The completed or terminated early studies include:  
 
• PN001  ([STUDY_ID_REMOVED])  (except for Part 3): a first -time-in-patients (FTIP), Phase I, dose -
escalation study evaluating AZD1775 both as monotherapy and combination therapy with 
gemcitabine, cisplatin, or carboplatin in adult patients with advanced solid tumors . 
 
• PN004 ([STUDY_ID_REMOVED]): a Phase II study evaluating AZD1775 combined with  carboplatin and 
paclitaxel in patients with platinum -sensitive p53 -mutant ovarian  cancer  
 
• PN005  ([STUDY_ID_REMOVED]):  a Phase I, dose -escalation study evaluating AZD1775 as monotherapy 
(Part 1), combination therapy with 5 -FU (Part 2), and combination therapy with 5 FU plus 
cisplatin (Part 3) in adult Japanese patients with advanced solid tumors was terminated early due 
to portfolio prioritization in oncology at [COMPANY_006] after 3 patients had been enrolled in Part 1 and 8 
patients had been enrolled in Part 2. Part 3 was not initiated.  
 
• PN008  ([STUDY_ID_REMOVED]) : a Phase I/IIa, dose -escalation study evaluating AZD1775 in 
combination with topotecan plus cisplatin in adult patients with cervical cancer was terminated 
early due to portfolio prioritization in oncology at [COMPANY_006] after 7 patients had been enrolled in the 
dose-escalation part of the study. The Phase IIa part was not initiated . 
 
• PN011  (Investigator Sponsored Study) : a Phase I study of single -agent AZD1775, in patients 
with refractory solid tumors, sponsored by [CONTACT_29630] (NCI) Cancer Therapy 
Evaluation Program in collaboration with [COMPANY_008] and [COMPANY_006]. This  study reported 
AZD1775  monotherapy activity in patients carrying BRCA mutations for the first time.  
 
• D6011C00001 ([STUDY_ID_REMOVED]; SCRI LUN 262): a lead -in Phase II multicenter, randomized, 
double -blind study comparing AZD1775 plus docetaxel with placebo plus  docetaxel in 
previously treated patients with non -small -cell lung cancer (NSCLC)  
 
• D6011C00002 ([STUDY_ID_REMOVED]; SCRI LUN 261): a Phase II study of AZD1775 plus 
pemetrexed and carboplatin followed by a randomized comparison of pemetrexed and 
carboplatin with o r without AZD1775 in patients with previously untreated stage IV non -
squamous NSCLC  
 
Ongoing:  
• D6010C00004 ([STUDY_ID_REMOVED]; SCRI GYN 49): a multicenter Phase II study of AZD1775 plus 
either paclitaxel, gemcitabine, carboplatin, or pegylated liposomal doxorubic in in patients with 
platinum -resistant epi[INVESTIGATOR_12253], fallopi[INVESTIGATOR_8916], or primary peritoneal cancer  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
12 
  
• D6010C00005 ([STUDY_ID_REMOVED]; SCRI REFMAL 384): a Phase I study evaluating AZD1775 in 
combination with olaparib in refractory solid tumors.  
 
• D6011C00003 (N CT02341456): a Phase Ib dose -finding study evaluating AZD1775 as 
monotherapy and in combination with carboplatin and paclitaxel in adult Asian patients with 
advanced solid tumors  
 
• D6015C00001 ([STUDY_ID_REMOVED]; SCRI REFMAL 383): a Phase I, dose escalation, safe ty and 
pharmacokinetic study of AZD1775 monotherapy (Schedule 1) in patients with advanced or 
metastatic solid tumors  
 
• D6015C00002 ([STUDY_ID_REMOVED]; SCRI REFMAL 412): a Phase I study assessing the safety, 
tolerability, and pharmacokinetics of AZD1775 in combin ation with MEDI4736 in patients with 
advanced solid tumors  
 
• D6015C00003 ([STUDY_ID_REMOVED]; SCRI REFMAL 398): a Phase Ib study to  determine the 
maximum -tolerated dose (MTD) of AZD1775 monotherapy (Schedule 2) in patients with locally 
advanced or metastatic solid  tumors.  
 
• NCI130032 ([STUDY_ID_REMOVED] ): AZD1775 for Advanced Solid Tumors  (CTEP Sponsored 
study)  
 
In Study PN001, of 1 76 evaluable patients who received AZD1775 (either single or multiple 
doses) as monotherapy or in combination with gemcitabine, cisplatin, or carboplatin, a partial 
response (PR) (confirmed and unconfirmed) was observed in 17 (9.7%) patients, and stable 
disease  (SD) was observed in 94 (53.4%) patients (AZD1775 Investigator’s Brochure[IB]) In 
Study PN001, 9 patients received AZD1775  monoth erapy. Single ascending doses of AZD1775 
up to 1300 mg were well tolerated; the maximum tolerated dose (MTD) was not  estab lished.  
 
In Study PN004, all patients were treated at the [ADDRESS_1100823] v1.1 in  
Part 1, there were 11 PRs (6 confirmed and 5 unconfirmed), and 3 SDs; 7 patients were  
evaluable by [CONTACT_28474] -125 with 3 CRs and 4 PRs. Final data for Part 2 is not available as of the  cut-
off date for this protocol.  
 
In Study PN005, patients in Part 1 received single -cycle BID dosing of AZD1775 for 5 days at 1 
of 2 dose levels  as monotherapy. A cohort of 3 patients was enrolled at the starting dose level of 
AZD1775 65 mg BID and no serious adverse events (SAEs) were experienced.  
 
No complete responses (CRs) or PRs were observed in either of Studies PN005 or PN008 at  the 
time that they were terminated.  
 
In Study PN011, patients received single -agent AZD1775 PO BID over 2.5 days per week for  2 
weeks in 3 -week treatment cycles. Twenty -five patients were enrolled to determine the  MTD 
using a 3+3 design. The MTD was establishe d at 225 mg by [CONTACT_1966] (PO) BID for 5  doses on 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
13 
 Weeks 1 and 2 of a 3 -week schedule. Six patients with BRCA -mutated solid tumors  were 
enrolled at the MTD. Partial responses were confirmed in two of the patients carrying  BRCA 
mutations (ovarian cancer patient a nd head/neck cancer patient). Paired tumor  biopsies were 
obtained from 5 patients treated at the MTD at baseline and after the 5th AZD1775 dose to 
determine the levels of pY15 -Cdk and γH2AX. The biopsies showed a  decrease in pY15 -Cdk 
levels (2/5 paired bio psies). The same biopsies were analyzed for  increases in γH2AX, an 
indicator of DNA damage. Three of the 5 biopsy pairs showed an  increase in γH2AX levels. 
DNA damage response was observed in this study through  provided paire d tumor biopsies . 
 
In Study D60 11C00001, 32 patients with NSCLC were treated with 225 mg AZD1775 BID  over 
2.5 days in combination with docetaxel (75 mg/m2 IV) administered on Day 1 followed  by 
[CONTACT_735929] 4 of each 21 -day cycle. The 3 patients (9.4%) that achieved PR by  
[CONTACT_393] v1.1 had TP53 mutations. Twenty -one patients (65.6%) had SD and 10 (47.6%) of  these 
patients had TP53 mutations. The planned Interim Analysis of 32 patients in the single cohort 
lead-in (Part A) suggested that toxicities associated with AZ D1775 given in co mbination with 
docetaxel were greater in frequency and severity than with docetaxel alone.  Additionally, the 
analysis revealed that it was very unlikely the target response rate would be  reached in this study 
and a decision was made to terminate enrolment.  
 
In Study D6011C00002, 14 patients with NSCLC were treated with 225 mg AZD1775 BID  over 
2.5 days in combination with pemetrexed 500 mg/m2 IV and carboplatin AUC [ADDRESS_1100824] -line NSCLC, such as immunotherapy,  which resulted 
in challenges in patient recruitment. In addition, the planned Interim Analysis  of Study 
D6011C00001 revealed that it was very unlikely that the target  response rate would  be reached, 
and increased gastrointestinal and hematologic toxicities associated with  AZD1775 were 
observed.  
 
In study NCI130032, the MTD was determined to be 300mg daily on days 1 -5 and 8 -12 every 21 
days (EORTC poster, Oct 2017) . In monotherap y studies carried out by [CONTACT_798193], a similar 
dosing regimen was  also determined to be the MTD  (data on file at AstraZe neca), therefore it 
will be the selected starting dose for this study.  
 
 
 
2.4   AZD1775 Pharmacokinetics  
 
The pharmacokinetic (PK) data of AZD1775 following a single oral administration (Study 
PN001) showed a  moderate rate of absorption with a time of maximum concentration (Tmax) 
occurring at 3 to 4  hours , 2 and 4 h ours on  day 1 and 3 respectively (IB v 15 p. 1 19). Post -peak 
plasma concentrations declined essentially in a mono -exponential manner  with a terminal 
elimination half -life (t1/2)  between 9.02 to 12.3  hours  13.2 hou rs at the 225 mg PMF dose (IB 
v15 p. 119).  Exposure as measured by  [CONTACT_798194] (Cmax) 
and area under the curve AUC (0-∞) increased in a dose -proportional manner over the dose range 
of 325 to 1300 mg.  
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
14 
 Following  single (100 to 325 mg) and multiple dose administrations of AZD1775 (25 to 325 mg 
BID and  100 to 200 mg  once daily [QD]) with carboplatin, cisplatin, and gemcitabine, plasma 
exposure  of AZD1775 was consistent with predictions based on the single -dose regimen. 
Preliminary  investigation of drug -drug interactions (DDIs) in Study PN001 suggest a  ~40%  
increase i n the exposure of AZD1775 in the presence of aprepi[INVESTIGATOR_053] (moderate CYP3A4 inhibitor)  
on both Day [ADDRESS_1100825] with the concomitant administration of steroids 
(moderate CYP3A4 inducers).  Preliminary studies also suggested that the Pre -marketed Oral 
Formulation of AZD1775 was  similar to that of the Fit -For-Purpose formulation.   
 
Based on the preliminary comparison of the results of AZD1775 PK parameters at the 225 mg 
dose, PK estimates in Asian patients were higher than in Western pati ents. After single dose 
administration on Cycle 0 Day 1 (monotherapy), Cmax and AUC at the 225 mg dose were 45% 
and 35% higher, respectively, in the Asian population as compared to the Western population 
(Study PN011). At steady state (Cycle 3 Day 1), a si milar trend of higher exposure in Asian 
patients was observed. Additional analysis/investigation will be conducted based on the 
emerging data to understand the exposure differences between the populations.  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
15 
 2.5   AZD1775 Safety  
 
Overall risks and benefits support the administration of oral AZD1775 according  to this clinical 
protocol.  The identified risks (expected events) for AZD1775 are described in section 5.4 
(Emerging Safety Profile) of the IB. Section 6.4 (Risk Management) of the IB .  
 
Based o n the safety data from the completed AZD1775 clinical studies and preliminary data 
from ongoing studies, adverse drug reactions to AZD1775 monotherapy include : anemia, 
neutropenia, thrombocytopenia, QTc prolongation, gastrointestinal events such as dyspeps ia, 
diarrhea, nausea and vomiting (with or without dehydration or serum electrolyte decreases), as 
well as decreased appetite.  
 
Based on information emerging during the clinical development program of AZD1775, potential 
risks with AZD1775 monotherapy inclu de asthenia/fatigue, febrile neutropenia, gastrointestinal 
hemorrhage, lymphopenia/lymphocyte count decreased, leukopenia/WBC count decreased, 
myalgia, stomatitis, sepsis and transaminases elevation.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
16 
 2.6  Cyclin E encoded by [CONTACT_798190]1 is a critical G1/S transit ion regulator  
 
Human cyclin E1 was initially discovered as one of several substitutes (cyclins A, B1, B2, C, D, 
and E) for G1 cyclin genes in yeast, and accumulated periodically through the cell cycle, 
initiating the G1 to S transition [14]. CCNE1 encodes the full -length 50 -KD E1 protein that 
interacts  with cyclin -dependent k inases 1 and 2 (CDK1 and CDK2) to activate  their kinase 
activity, a requirement for G1 -S transition [15]. In normal dividing cells, cyclin E1 is highly cell 
cycle -dependent, peaking in late G1 and reaching i ts nadir in G2 -M and early G1 phases [16]. 
Early in the G1 phase, increases in c -Myc levels promote cyclin D transcription, which activates 
CDK4 and CDK6 to phosphorylate their target protein, such as retinoblastoma (Rb) and its 
complex partners (p130 and p 107) [17]. Activated Rb acts as a tumor suppressor to main tain 
cells in  the G1/G0 phase through binding the inhibiting E2F in the absence of cyclin E/CDK 
complex. Upon Rb hyperphosphorylation by  [CONTACT_4721] D/CDK complexes, E2Fs are released from 
its inhibitory complex and can initiate CCNE1 expression [18]. Onc e activated, cyclin E1/CDK2 
becomes independent of mitogenic stimuli and can further upregulate its own expression by 
[CONTACT_798195]/E2F complexes, triggering the G1 -S transition. 
Cyclin E1/CDK complexes can be silenced by [CONTACT_798196]1 promoter silencing, protein inhibition by 
p21Cip1 and p27Kip1, degradation by [CONTACT_798197]7 tumor suppressor pathway [19], and microRNA -
mediated inhibition (miR -15a, miR -15b, miRNA -16) [20].  
 
The function for cyclin E1 to induce S phase entry depends on its interactions with CDK1 and 
CDK2 [21], mediating cell cyc le progression from G1 to S phase; DNA replication and 
transcription; centriole duplication, centrosome separation, and endoreduplication; activating 
BRCA1/[ADDRESS_1100826] for DNA repair and confer relative chemotherapy 
resistance; and many other biological processes such as apoptosis, pre -mRNA splicing, synaptic 
function and epi[INVESTIGATOR_263574], as described in Figure 2 [22]. 
 
Cyclin E demonstrates high oncogenic potential  and their amplification can induce tumor 
formation both in vivo and in vitro [23-26]. CCNE1 is frequently amplified in many human 
tumors, with the frequency of amplification ranging from 2 to 40% [27]. CCNE1 amplification 
results in cyclin E1 overexpression, which play an important role in cancer progression, and 
correlates with worse overall survivals [28-34], as well as disease survival as shown in Figure 3 
(data from Dr. K. Keyomarsi’s laboratory).  
 
 
 
 
 
 
 
 
 
 
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
17 
  
 
 
 
 
  
Figure 2. Summary of cyclin E1 functions. Cyclin E1 functions in 
cell cycle progression, inhibition of apoptosis, and DNA 
transcription, replication, and repair. Less characterized functions 
may include centriole duplication, pre -mRNA splicing, and 
epi[INVESTIGATOR_798156]. Kanska J et al: Gyn Onc, 2016 
(http://dx.doi.org/10.1016/j.ygyno.2016.07.111)  
Figure 3: Overexpression of cyclin E and 
pCDK2 was associated with worse disease -
free survival in patients with triple negative 
breast cancer. (Chen X et al: unpublished  
data). 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
18 
 2.7  CCNE1 Amplification Sensitizes Cancer Cells to AZD1775  
 
Overexpression of cyclin E has been shown to promote genomic instability by [CONTACT_798198] G1 to S transition [35-37]. Wee1 kinase, which prevents 
premature mitotic entry by [CONTACT_201748] s, may be essential when cyclin E is overexpressed in 
order to prevent massive DNA damage and cell death [38-40]. Recent findings from a genome -
wide knockout screen revealed that absence of CDK2 decreases sensitivity to Wee1 kinase 
inhibition [41]. Furthermore, [CONTACT_9580] and her group at MD Anderson have 
shown that overexpression of cyclin E is significantly assoc iated (85%; p<0.001) with active 
CDK2 (phoshpo -CDK2) in tumor samples from 1,[ADDRESS_1100827] cancer patients [28, 42] .   
 
Collectively, these studies suggest that overexpression of cyclin E could predict response to Wee 
[ADDRESS_1100828] this hypothesis, we initially evaluated the sensitivity of 6 TNBC cell 
lines to a clinically available Wee 1 k inase inhibitor, AZD1775 [43], as a function of several cell 
cycle modulators.  Results revealed t hat the expression of cyclin E was highly predictive (r=0.90) 
of response to AZD1775 in all 6 TNBC cell lines (Chen X et al: unpublished data, Figure 4). 
Consistent with this conclusion, the levels of p -CDK1 (Y15, a known downstream effector of 
Wee1 kinase ) and p -CDK2 (T160) were moderately (2/6 cell lines) predictive of AZD1775 
sensitivity among other key cell cycle regulators.   
 
Figure 4: Correlation between cyclin E normalized protein 
level and AZD1775 sensitivity (r= -0.90) from IC50 values.  
(Chen X et  al: unpublished data).  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
19 
 In two of the TNBC cell lines (HCC1806 and MB231), the knockdown of cyclin E by [CONTACT_798199], 
desensitized both cell lines to AZD1775, compared to their scrambled controls. Induction of 
cyclin E expression in 76NE6 (a human mammary epi[INVESTIGATOR_114239]) and MDA23 1 cells 
significantly (p <0.001) increased AZD1775 sensitivity, compared to their uninduced controls. 
Furthermore, induction of the tumor specific cytoplasmic -localized low molecular weight cyclin 
E (LMWE) [44, 45]  in 76NE6 cells also increased sensitivity to AZD1775, but not more than full 
length cyclin  E. We interrogated the sensitivity of AZD1775 in vivo , by [CONTACT_12780][INVESTIGATOR_798157] (PDX) models from TNBC patients: PDX1 has normal copy number 
and low cyclin E expression, while PDX2 and PDX3 exhibit amplification and overexpression of 
cyclin E. CDK2, p -CDK2 and p -CDK1 levels were also co -overexpressed with cyclin E in PDX2 
and PDX3. Each PDX model was treated with either vehicle or 50mg/kg AZD1775 for 4 cycles 
and sacrificed when maximum allowable tumor burden were reached. Consisten t with our in 
vitro  results, AZD1775 treatment significantly decreased tumor burden and improved survival of 
cyclin E overexpressing PDX2 and PDX3 models, with little to no inhibition of PDX1 model 
(Chen X et al: unpublished data, Figure 5). Collectively, these results suggest cyclin E 
overexpression can predict response to Wee1 kinase inhibition.  
The clinical data to use AZD1775 in patients with advanced solid tumors is emerging from the 
ongoing phase I study ([STUDY_ID_REMOVED]; [COMPANY_008] Study D6015C00001; RE FMAL 383), 
which is a single agent AZD1775 study . In a phase II trial PN004 that investigated the 
combination of AZD1775 and platinum -containing chemotherapy for the treatment of patients 
with TP53 mutant recurrent platinum -sensitive ovarian cancer (NCT013 [ZIP_CODE]), enrollment 
Figure 5: PDX1 has normal copy number and low cyclin E expression, while PDX2 and 
PDX3 exhibit amplification and overexpression of cyclin E. Each PDX model was 
treated with either vehicle or 50mg/kg AZD1775 via oral gavage BI D x 2 days every 
week for 4 weeks. AZD1775 treatment significantly decreased tumor burden and 
improved survival of cyclin E overexpressing PDX2 and PDX3 models, with little to no 
inhibition of PDX1 model. (Chen X et al: unpublished data).   
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
20 
 started with 15 patients for open -labeled safety run -in study (Part A) followed by 121 patients 
(Part B) who were randomized to receive AZD1775 plus paclitaxel and carboplatin or placebo 
plus paclitaxel and carboplatin (Laing N et al: Ge netic analysis of tumors from a Phase II trial 
evaluating AZD1775, carboplatin and paclitaxel in patients with TP53 -mutant ovarian cancer. 
AACR [ADDRESS_1100829]). Two patients (#10, and #13) were identified to have CCNE1 
amplification in Part A: both ach ieved partial responses for more than one year. In Part B, two 
patients were found to have CCNE1 amplification in AZD1775 plus paclitaxel and carboplatin 
group: one had stable disease (#25), and the other achieved complete remission (#29); three 
patients w ere identified to have CCNE1 amplification in placebo plus paclitaxel and carboplatin 
group: one had stable disease (#38), and the other two achieved partial responses (#35, and #44).   
 
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100830] provided the mechanistic and preclinical evidence to support 
the use of cyclin E a biomarker of response to AZD1775 in TNBC [43]. We show that the 
replication stress pathway activated upon cyclin E  overexpression results in sensitivity to Wee1 
kinase inhibition. Evaluation of cyclin E overexpression resulted from CCNE1 amplification can 
readily be used as an integral biomarker in future clinical trials, to guide identification of patients 
who are li kely to respond to AZD1775. As in Figure 6, CCNE1 amplifications have been 
observed in more than 7.5% of many tumor types: uterine, breast, ovarian, pancreatic, bladder, 
gastric, esophageal, lung cancers and sarcoma. Therefore, it might be appropriate to c onduct a 
phase II basket study in patients with advanced solid tumors harboring CCNE1 amplification.  
 
In our own institutional experien ce at MD Anderson, [CONTACT_798227] -Bernstam and her 
colleagues have collected tumor specimens from 3807 patients with advanced solid tumors. 
Cyclin E amplifications were identified on multiple genomic testing platforms, as shown in 
Table 1, ranging from 1. 3% to 6.1%. In these 3807 patients, Cyclin E amplifications were 
detected in 108 patients (2.8%), frequently in patients with bladder (n=3), breast (n=10), bile 
duct | cholangiocarcinoma (n=6), colorectal (n=9), endometrial (n=12), gall bladder (n=11), 
gastric (n=4), liver (n=8), lung (n=7), pancreatic (n=4), primary peritoneal  (n=6), ovarian cancer 
(n=14), and sarcoma (n=4), as shown in Figure 7. 
 
Figure 6: Frequency of CCNE1 amplification in different pathologic 
diagnoses. (K. Keyomarsi et al: unpublished data).  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
22 
  Table 1: Rates of Cyclin E Amplification - according to NGS platforms  
Platform  # Amplified/# of Tests  Rate  
Oncomine  2/38 5.3%  
STGAv1  24/1803  1.3%  
FoundationOne  68/1792  3.8%  
Guardant360  16/263 (overall)  6.1%  
6/263  (++)  2.3%  
0/263 (+++)  0% 
 
 
 
 
  
Bile Duct | Cholangiocarcinoma, [ADDRESS_1100831] , 10
Colorectal , 9
Endometrial/Uterine , 
12
Gall Bladder , 11
Gastric/Stomach , 4Liver , 8Lung , 7Ovarian , 14Pancreatic , 4Primary Peritoneal , 6Sarcoma , 4Other , 10Figure 7: Disease Types Observed with CCNE1 
Amplification
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
23 
 Overexpression of cyclin E has been shown to promote genomic instability by [CONTACT_798198] G1 to S transition. Wee1 kinase, which prevents 
premature mitotic entry by [CONTACT_798200], may be essential when cyclin E is ov erexpressed in 
order to prevent massive DNA damage and cell death. We hypothesize that cancer cells 
harboring CCNE1 amplification that leads to cyclin E overexpression, will be highly sensitive to 
the treatment with AZD1775, a Wee1 inhibitor, and that the objective response rate (ORR) 
defined as complete responses (CRs), and partial responses (PRs) will be observed in greater 
than 25% of patients with CCNE1 amplified advanced solid tumors who receive the treatment 
with AZD1775.  
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
24 
 2.9   Correlative Studies – Background  and Rationale  
 
Introduction  
Overexpression of cyclin E has been shown to promote genomic instability by [CONTACT_798198] G1 to S transition. Wee1 kinase, which prevents 
premature mitotic entry by [CONTACT_798200], may be essential when cyclin E is ov erexpressed in 
order to prevent massive DNA damage and cell death. We hypothesize that CCNE1 
amplification in cancer cells leads to an  overexpress ion of cyclin E 1 protein , which will sensitize 
cancer cells  to the treatment with AZD1775, a Wee1 inhibitor . The consequential disruption of 
intra-S phase and G2/M cell cycle checkpoint s by [CONTACT_798201]1775 will resu lt in prematu re 
mitotic entry , inducing significantly greater mitotic catastrophe and apoptosis in cyclin E1 
overexpressed cells . We will test this hypothesis in this clinical study with the help of the 
following correlative studies.  
 
In order to further define the molecular environment of CCNE1 amplification along with Wee1 
inhibition , we will  validat e several key biological players using next generation sequencing and 
cytogenetic platforms at various  treatment time  points listed in Table 2 . 
 
 
Table 2.  Laboratory Correlates – Biomarker Plan  
Biomarker 
Name  
[CONTACT_798221] 
[INVESTIGATOR_278558]  
(CLIA: Y/N)  Use (Integral, 
Integrated, or 
Exploratory) AND 
Purpose  Tissue/Body 
Fluid Tested and 
Timing of Assay   
M/O  Funding 
Source(s)  
CCNE1 
amplification   
(S. Fu /MD 
Anderson)  Cytogenetics (Y), or a 
next generation 
sequencing platform 
(Y) 
CLIA: Y  Integr al 
To identify patients for 
subgroup enrollment.  
To correlate responses.  Tumor and blood  
Archival or 
baseline biopsy  M Standard 
of patient 
care 
pCDK, pHH3, 
gH2AX  
([CONTACT_798228]/PADIS 
Laboratory, 
FNCLR)  
 Quantitative 
immunofluorescence  
 
CLIA:  N Integrated  
 
To investigate 
pharmacodynamic 
responses  Tumor biopsy 
(frozen tissue)  
Pre-study, C1D10 
at 4h post dose , 
and at progression  M – Pre-
study  and 
C1D10 at 
4h post 
dose  
O-at 
progression  NCI 
Pre-identified 
mutations  
(F. Meric -
Bernstam /MD 
Anderson)  A next generatio n 
sequencing platform  
CLIA: N  Exploratory  
To identify biomarkers 
of responses and 
acquired resistance  Plasma  
Pre-study, C1D8, 
C2D1 , C2D8, and 
at end of study  M – Pre-
study  
O – All 
other times  TBA 
Cytokines and 
chemokines  
(F. Meric -
Bernstam /MD 
Anderson)  Meso Scale Discovery 
platform  
CLIA: N  Exploratory  
To identify biomarkers 
of responses and 
acquired resistance  Plasma  
Pre-study, C1D8, 
C2D1, C2D8 and 
at end of study  M – Pre-
study  
O – All 
other times  TBA 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
25 
 Biomarker 
Name  
[CONTACT_798221] 
[INVESTIGATOR_278558]  
(CLIA: Y/N)  Use (Integral, 
Integrated, or 
Exploratory) AND 
Purpose  Tissue/Body 
Fluid Tested and 
Timing of Assay   
M/O  Funding 
Source(s)  
Cyclin E1 , 
pCDK2  (K. 
Keyomarsi / MD 
Anderson   Immunohistochemistry  
CLIA: N  Exploratory  
To identify biomarkers 
of response and 
acquired resistance  Tumor  
Pre-study, C1D10 
at 4h post dose , 
and at progression     
O  TBA  
Molecular 
signatures  
(F. Meric -
Bernstam /MD 
Anderson)  Targeted exome by a 
next generation 
sequencing platform 
and RNA -seq analysis  
CLIA: N  Exploratory  
To identify biomarkers 
of responses and 
acquired resistance  Tumor  and blood  
Pre-study, C1D10 
at 4h post dose , 
and at progression   O MD 
Anderson 
IPCT  
 
 
Assay for CCNE1 amplification  
 
Oncomine – a next generation sequencing platform for CCNE1 amplification  
 
Solid Tumor Genomics Assay v1 is one of the Oncomine Cancer Panels conducted at MD 
Anderson. This next generation sequencing -based analysis (PCR -based sequencing) for the 
detection of somatic mutations in the coding sequencing of 128 genes and selected copy number 
variations (amplification) in 49 genes (overlap: 134 genes total) is performed on the DNA 
extracted from the tumor sample in a CLIA -certified molecular diagno stics laboratory at MD 
Anderson. For clinical purposes, the effective lower limit of detection of this assay (analytical 
sensitivity) for single nucleotide variations is in the range of 5% - 10% (one mutant allele in the 
background of nineteen - nine wild type alleles). Sensitivity for amplifications depends on both 
input tumor percentage and the amplitude of the gene amplification. The analytic pi[INVESTIGATOR_798158] -amplicon performance differences and total sample loading,  
but does not attempt to correct for tumor percentage. A nominal threshold of [ADDRESS_1100832] reporting to high -confidence amplification calls.  
 
FISH – fluorescence in situ hybridization for CCNE1 amplification  
 
The FISH  probe for CCEN1 19p12 (RP11 -345 J21) will be acquired from BACPAC Resources 
(Oakland, CA). The probe will be labeled with SpectrumOrange or SpectrumGreen using a nick 
translation kit (Abbott Laboratories, Abbott Park, IL). Tissue sections will be processe d for 
removal of protein, denaturation, hybridization, and posthybridization washing, and then will be 
counterstained with DAPI [INVESTIGATOR_51381] (Abbott Laboratories) and examined using a fluorescence 
microscope (Olympus, Tokyo, Japan) equipped with a Triple Bandpass Fi lter set (Abbott 
Laboratories) for DAPI [INVESTIGATOR_51381], SpectrumOrange, and SpectrumGreen. Scoring and evaluation of 
FISH slides will be performed manually by [CONTACT_798202] 20 tumor cell nuclei per sample. Gene amplification w as determined according to the 
American Society of Clinical Oncology/College of American Pathologists criteria for ERBB2 
amplification.  
 
Assay for pCDK, pHH3, gH2AX  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
26 
  
Quantitative immunofluorescence assays will be performed as previously described (53).  
 
Assay for pre -identified mutations  
 
Whole blood will be collected in EDTA –containing tubes, centrifuged and spun twice within 2 
hours to yield plasma. The QIAamp Circul ating Nucleic Acid kit (Qiagen, Valencia, CA) will be 
used to isolate cfDNA, and 16 -100 ng of unamplified cfDNA will be tested with a multiplex 
ddPCR Screening Kit (Bio -Rad, Pleasanton, CA) using the QX200 Droplet Digital PCR platform 
(Bio-Rad). The lower  limit of detection is approximately 0.2% MAF (mutation allelic frequency) 
for the multiplexed screening assay and <0.1% MAF per single well for the mutation -specific 
assays.  
 
Assay for circulating cytokines and chemokines  
 
Circulating cytokines and chemok ine will be measured using the MesoScaleDiscovery (MSD) 
platform. The MSD technology uses pairs of antibodies recognizing different epi[INVESTIGATOR_798159]/chemokine. The primary antibodies are spotted onto the well of a 96 -well plate 
(several spots recognizing different cytokines/chemokines per well). The secondary antibody (as 
an ELISA sandwich) is labeled with a sulfo -tag that allows using an electrical current to measure 
electrochemiluminescence as the signal. This technology is sensitive and has a broad dynamic 
range (0.2 -[ZIP_CODE] pg/ml). The samples from each time point of each patient will be analyzed in 
duplicate. Each assay requires 25 µl of plasma/well. Standards for each cytokine (0 -10,000 
pg/ml) will be run on each multiplex assay plate. The d ata will be acquired on the V -plex® 
Sector Imager 2400 plate reader and analyzed using the Discovery Workbench 4.0 softw are 
(MSD, Rockville, Maryland).  
 
Assay for cyclin E1  and pCDK2  
 
Immunohistochemistry for cyclin E and p -CDK2 w ill be  performed using two rabbit polyclonal 
antibodies; sc198 (Santa Cruz Biotechnology, Dallas, TX) at a dilution 1:1000 and Thr160 (Cell 
Signaling Technology, Danvers, MA) at a dilution of 1:100 and developed with the 
VECTASTAIN Elite ABC kit (Dako, Glostrup,  Denmark). Nuclear and cytoplasmic staining 
scores will be independently assigned according to their staining intensity and combined to 
generate the low and high values. For p -CDK2 the intensity and the extent of the staining 
generated the final immunoreac tivity score will be determined by [CONTACT_798203], with a minimum score of 0 and maximum score of 18; scores of ≥6 
indicated positivity.  
 
Assay for molecular signatures  
 
DNA will be extracted from tumor specim ens will be analyzed by [CONTACT_48832] 
(i.e., Solid Tumor Genomics Assay v1) to detect targeted exome aberrations.  
 
RNA will be isolated from tumor specimens using the the Qiagen RNeasy AllPrep method 
(Qiagen Sciences, Valencia, CA) and stored  at -80oC until further use. RNA integrity will be 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
27 
 monitored using a Bioanalyzer and the Agilent RNA 6000 Pi[INVESTIGATOR_798160] (Agilent Technologies, 
Santa Clara, CA). An RNA integrity number greater than [ADDRESS_1100833] reverse transcription. The library will be quantified for Illumina HiSeq2000 50 base sing le 
read (SR50) and sequenced on the HiSeq2000 Sequencer, to identify novel genes and splice 
variants, and to detect single nucleotide polymorphisms.   
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100834] one of the histologically advanced solid tumors harboring CCNE1 
amplification: Their diseases are refractory to, or do not have, standard -of-care therapy; or 
they declined standard -of-care therapy. CCNE1 amplification is defined in a Cli nical 
Laboratory Improvement Amendments (CLIA) -certified laboratory: CCNE1 Amplification > 
7 based on targeted custom Ampliseq panel on the Ion Torrent PGM; or CCNE1 
amplification on alternate CLIA platforms such as Foundation One, UW -OncoPlex – Cancer 
Gene Panel, MSK -IMPACT, Solid Tumor Genomic Assay (Life Technologies), etc. will also 
be eligible to be treated after PI [INVESTIGATOR_41473].  Patients with known CCNE1 amplification on 
local or commercial platforms can start treatment after planned biopsy or submission  of 
recent archival sample. Central NGS CCNE1 and FISH testing will be performed to confirm 
the result.  
 
2. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.  
 
3. Male or female sex and age ≥18 years  
 
4. Has read and understan ds the informed consent form (ICF) and has given written IC F prior to 
any study procedures.  Patients with Impaired Decision Making Capacity (IDMC) must have 
a close caregiver or Legally Authorized Representative (LAR) . 
 
5. Any prior radiation must have been c ompleted at least [ADDRESS_1100835] recovered from any acute adverse effects prior  to the start of study 
treatment . 
 
6. Eastern Cooperative Oncology Group  (ECOG) Performance Status score of  0-1. 
 
7. Baseline laborat ory values within 14 days of study drug(s) initiation:  
• Absolute neutrophil count (ANC) ≥1500/  µL 
• Hemoglobin (Hg b) ≥ 9g/dL  for mono -therapy  
• Platelets ≥ 100,000/ µL 
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit 
of normal (ULN) or ≤ [ADDRESS_1100836] if known hepatic metastases.  
• Serum bilirubin < ULN or < 1.[ADDRESS_1100837] in patients with liver metastases; or total bilirubin 
< 3.[ADDRESS_1100838] bilirubin WNL in patients with well documented Gilbert’s 
Syndrome. Serum creatinine ≤ 1.[ADDRESS_1100839], or calculated  creatinine clearance (CrCl) ≥ 45 
mL/min as calculated by [CONTACT_16424] -Gault method or 24 -hour measured urine CrCl ≥ 
45 mL/min.  
CrCl (gl omerul ar filtration rate [GFR]):   a where F= 0.85 for females and F=1 for male 
= (140 -age) x (weight/kg) x Fa / (72 x serum creatinine mg/dL ) 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100840] within 3 days  prior to the start of  study 
treatmen t (see Appendix D ).  Male  patients willing to  abstain or  use barrier contraception 
(i.e. condoms) for the duration of the study and for 3 months  after treatment stops (see  
Appendix D). 
 
9. Willingness and ability to comply with  study and follow -up procedures.  
 
10. Ability to take oral medications without medical history of malabsorption or other chronic 
gastrointestinal disease, or other conditions that may hamper compliance and/or absorption of 
the study agent.  
 
11. No prior treatment with Wee1 kinase inhibition.  
 
12. Provision of an archival tissue block, or 10 formalin -fixed paraffin -embedded (FFPE) slides, 
if available, and having biopsiable disease and agreeing to pre -treatment and on -study 
biopsies.  
 
 
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
30 
 3.2   Patient Exclusion Criteria  
 
Patients who meet any of the f ollowing criteria will not be eligible for the study.  
 
1. Use of anti -cancer treatment drug ≤ 21 days or 5 half -lives (whichever is shorter)  prior to the 
first dose of AZD1775. For drugs for which 5 half -lives is ≤ 21 days, a  minimum of 10 days 
between termi nation of the prior treatment and administration  of AZD1775 treatment is 
required.  
 
2. Previous radiation therapy completed  ≤ 7 days prior to the start of study drugs.  
 
3. Major surgical procedures ≤ 28 days of beginning AZD1775 , or minor surgical  procedures ≤ 
7 days. No waiting period required following port -a-cath or other  central venous access 
placement.  
 
4. Unresolved Grade 2  toxicity from prior therapy (except alopecia or anorexia).  
 
5. Patient has an inability to swallow oral medications. Note: Patient may not have a  
percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral  nutrition 
(TPN).  
 
6. No other anticancer -therapy (chemotherapy, immunotherapy, hormonal anti -cancer therapy, 
radiotherapy [except for pal liative local radiotherapy]), biological therapy or other novel 
agent is to be permitted while the patient is receiving study medication. Patients on LHRH 
analogue treatment for more than 6 months are allowed entry into the study and may 
continue at the di scretion of the Investigator . 
 
7. Known malignant central nervous system (CNS) disease other than neurologically stable, 
treated brain metastases – defined as metastasis having no evidence of progression or 
hemorrhage for at least [ADDRESS_1100841] 14 days prior to enrolment.  
 
8. Patient has had prescription or non -prescription drugs or other products known to be  
sensitive to CYP3A4 substrates or CYP3A4 substrates w ith a narrow therapeutic  index, or to 
be moderate to strong inhibitors/inducers of CYP3A4 which cannot be  discontinued [ADDRESS_1100842] dose 
of study drug. Co -administration of aprepi[INVESTIGATOR_798161] . 
The use of sensitive substrates of CYP3A4, such as atorvastatin, simvastatin and lovastatin, 
is also prohibited in this study  
 
9. Herbal preparations are not allowed throughout the study. These her bal medications include 
but are not limited to: St. John's wort, kava, ephedra (ma  hung), gingko biloba, 
dehydroepi[INVESTIGATOR_2119] (DHEA), yohimbe, saw palmetto and  ginseng. Patients should stop 
using these herbal medications [ADDRESS_1100843]  dose of stu dy treatment .  
 
10. Any known hypersensitivity or contraindication to the components of the study  drug 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100844] 6 months as  defined by 
[CONTACT_57929] (NYHA) ≥ Class 2 . 
• Unstable ang ina pectoris  
• Congestive heart failure  
• Acute myocardial infarction  
• Conduction abnormality not controlled with pacemaker or medication  
• Significant ventricular or supraventricular arr hythmias (patients with chronic rate-
controlled  atrial fibrillation in the a bsence of other cardiac abnormalities are  eligible)  
 
12. Mean resting corrected QTc interval using the Fridericia formula (QTcF) >450  msec/male 
and >470 msec/female (as calculated per institutional standards)  obtained from 3 
electrocardiograms (ECGs) 2 -5 minut es apart at study entry, or  congenital long QT 
syndrome.  
 
13. Pregnant or breastfeeding women . 
 
14. Serious active infection at the time of study entry, or another serious underlying  medical 
condition that would impair the ability of the patient to receive study  treatment.  
 
15. Symptomatic and uncontrolled metastasis in the central nervous system or leptomeningeal or 
lymphangitic carcinomatosis.  
 
16. Presence of other active invasive cancers that do not harbor CCNE1 amplification.  
 
17. Grade 2 or higher peripheral neuro pathy.  
 
18, Human immunodeficiency virus requiring HAART treatment due to unknown drug -drug 
interactions or has known active hepatitis B (e.g., HBsAg reactive or C virus (e.g., HCV RNA 
(quantitative) is detected) infection   
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
32 
 3.3   Inclusion of Women and Minorities  
 
NIH policy requires that women and members of minority groups and their subpopulations be 
included in all NIH -supported biomedical and behavioral research projects involving NIH -
defined clinical research unless a clear and compelling rationale and justification establishes to 
the satisfaction of the funding  Institute & Center  (IC) Director that inclusion is inappropriate 
with respect to the health of the subjects or the purpose of the research.  Exclusion under other 
circumstances must be design ated by [CONTACT_25513], NIH, upon the recommendation of an  IC 
Director based on a compelling rationale and justification.  Cost is not an acceptable reason for 
exclusion except when the study would duplicate data from other sources.  Women of 
childbearing po tential should not be routinely excluded from participation in clinical research.  
Please see http://grants.nih.gov/grants/funding/phs398/phs398.pdf . 
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
33 
 4.   REGISTRATION PROCEDURES  
4.1   Investigator and Research Associate Registration with CTEP  
 
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy 
require all individuals contributing to NCI -sponsored trials to register and to renew their 
registration annually.  To register, all individuals must obtain a Cancer Therapy Evaluation 
Program (CTEP) Identity and Access Management (IAM) account 
(https:// ctepcore.nci.nih.gov/iam ).  In addition, persons with a registration type of Investigator 
(IVR), Non -Physician Investigator (NPI[INVESTIGATOR_6731]), or Associate Plus (AP) (i.e., clinical site staff 
requiring write access to OPEN or RAVE or acting as a primary s ite contact) must complete their 
annual registration using CTEP’s web -based Registration and Credential Repository (RCR) 
(https://ctepcore.nci.nih.gov/rcr).  Documentation requirements per registration type are outlined 
in the table below.  
 
Documentation R equired  IVR NPI[INVESTIGATOR_6732] A 
FDA Form 1572      
Financial Disclosure Form      
NCI Biosketch (education, training, employment, license, and 
certification)      
HSP/GCP training      
Agent Shipment Form (if applicable)      
CV (optional)      
 
An active CTEP -IAM user account and appropriate RCR registration is required to access all 
CTEP and CTSU (Cancer Trials Support Unit) websites and applications.  In addition, IVRs and 
NPI[INVESTIGATOR_798162] 1572 in RCR to allow the following:  
• Added to a site roster  
• Assigned the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN  
• Act as the site -protocol PI [INVESTIGATOR_6734]  
• Assigned the Clinical Investigator ( CI) role on the Delegation of Tasks Log (DTL).     
 
Additional information can be found on the CTEP website at 
<https://ctep.cancer.gov/investigatorResources/default.htm >.  For questions, please contact [CONTACT_25514] < [EMAIL_088]  >. 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
34 
  
 
4.2   Site Registration  
 
This study is supported by [CONTACT_6818] (CTSU).  
Each investigator or group of investigators at a clinical site must obtain IRB approval for this 
protocol and submit IRB approval and supporting documentation to the CTSU Regulatory Office 
before they can be approved to enroll patients.  Assignment of site  registration status in the 
CTSU Regulatory Support System (RSS) uses extensive data to make a determination of whether 
a site has fulfilled all regulatory criteria including but not limited to the following:  
• An active Federal Wide Assurance (FWA) number  
• An active roster affiliation with the Lead Network or a participating organization  
• A valid IRB approval  
• Compliance with all protocol specific requirements  
 
In addition, the site -protocol Principal Investigator (PI) must meet the following criteria:  
• Active r egistration status  
• The IRB number of the site IRB of record listed on their Form FDA 1572  
• An active status on a participating roster at the registering site  
Sites participating on the NCI CIRB initiative that are approved by [CONTACT_33978]. For sites 
using the CIRB, IRB approval information is received from the CIRB and applied to the RSS in 
an automated process.  Signatory Institutions must submit a Study Specific Worksheet for Local 
Context (SSW) to the CIRB via IRBManager to indicate their intent to open the study locally.  
The CIRB’s approval of the SSW is then communicated to the CTSU Regulatory Office.  In 
order for the SSW approval to be processed, the Signato ry Institution must inform the CTSU 
which CIRB -approved institutions aligned with the Signatory Institution are participating in the 
study.  
 
Downloading Regulatory Documents  
 
Site registration forms may be downloaded from the [ADDRESS_1100845] be 
associated with the Corresponding or Participating pr otocol organization in the RSS.  
 
• Go to https://www.ctsu.org  and log in using your CTEP -IAM username [CONTACT_2383].  
• Click on the Protocols tab in the upper left of your screen.  
• Either enter the protocol # in the search field at the top of the protocol tree, or  
• Click on the By [CONTACT_56124], then select LAO -TX035 , and protocol 
1013 6. 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
35 
 • Click on LPO Do cuments, select the Site Registration documents link, and download and 
complete the forms provided.  (Note: For sites under the CIRB initiative, IRB data will load to 
RSS as described above .) 
 
 
Requirements For NCI [ZIP_CODE]  Site Registration:  
• IRB approval (For sites not participating via the NCI CIRB; local IRB documentation, an 
IRB-signed CTSU IRB Certification Form, Protocol of Human Subjects Assurance 
Identification/IRB Certification/Declaration of Exemption Form, or combination is 
accepted ) 
• Local informed consent document  
 
Submitting Regulatory Documents  
Submit required forms and documents to the CTSU Regulatory Office, where they will be 
entered and tracked in the CTSU RSS.   
Regulatory Submission Portal: www.ctsu.org   (members’ area) → Regulatory Tab →Regulatory 
Submission  
When applicable, original documents should be mailed to:  
CTSU Regulatory Office  
[ADDRESS_1100846]  
Philadelphia, PA [ZIP_CODE]  
 
Institutions with patients waiting that are unable to use the Portal should alert the CTSU 
Regulatory Office immediately at 1 -[PHONE_102] in order to receive further instruction and 
support.  
 
Checking Site Registration Status  
 
You can verify your site reg istration status on the members’ section of the CTSU website.   
• Go to https://www.ctsu.org  and log in to the members’ area using your CTEP -IAM 
username [CONTACT_2383]  
• Click on the Regulatory tab at the top of your screen  
• Click on the Site Registration tab  
• Enter your 5 -character CTEP Institution Code and click on Go  
 
Note: The status given only reflects compliance with IRB documentation and institutional 
compliance with protocol -specific requirements as outlined by t he Lead Network. It does not 
reflect compliance with protocol requirements for individuals participating on the protocol or 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
36 
 the enrolling investigator’s status with the NCI or their affiliated networks.  
4.3   Patient Registration  
 
OPEN / IWRS  
 
Patient enrollment will be facilitated using the Oncology Patient Enrollment Network (OPEN).  
OPEN is a web -based registration system available to users on a 24/7 basis.  It is integrated with 
the CTSU Enterprise System for regulatory and roster data inter change and with the Theradex 
Interactive Web Response System (IWRS) for retrieval of patient registration/randomization 
assignment.  Patient enrollment data entered by [CONTACT_25517] / IWRS will automatically 
transfer to the NCI’s clinical data managem ent system, Medidata Rave.  
 
For trials with slot reservation requirements, OPEN will connect to IWRS at enrollment initiation 
to check slot availability.  Registration staff should ensure that a slot is available and secured for 
the patient before completi ng an enrollment.  
 
The OPEN  system will provide the site with a printable confirmation of registration and 
treatment information.   Please print this confirmation for your records.   
 
 
OPEN/IWRS User Requirements  
 
OPEN/IWRS users must meet the following requ irements:  
• Have a valid CTEP -IAM account ( i.e., CTEP username [CONTACT_2383]).  
• To enroll patients or request slot reservations:  Be on an ETCTN Corresponding  or 
Participating Organization roster with the role of Registrar.  Registrars must hold a 
minimum of an  AP registration type.   
• To approve slot reservations or access cohort management:  Be identified to Theradex as the 
“Client Admin” for the study.  
• Have regulatory approval for the conduct of the study at their site.  
 
Prior to accessing OPEN/IWRS, site sta ff should verify the following:  
• All eligibility criteria have been met within the protocol stated timeframes.    
• If applicable, all patients have signed an appropriate consent form and HIPAA authorization 
form.  
 
 
OPEN/IWRS Questions?  
 
Further instructional information on OPEN is provided on the OPEN tab of the CTSU website at 
https://www.ctsu.org  or at https://open.ctsu.org .  For any additional questions contact [CONTACT_110694] 1 -[PHONE_103] or [EMAIL_013] .  
 
Theradex has developed a Slot Reservations and Cohort Management User Guide, which is 
available on the Theradex website:  http://www.theradex.co m/clinicalTechnologies/?National -
Cancer -Institute -NCI-11. This link to the Theradex website is also on the CTSU website OPEN 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100847] the Theradex Helpdesk  at 
[PHONE_7135]  or Theradex main numb er 609 -799-7580; [EMAIL_411] . 
 
 
4.4   General Guidelines  
 
Following registration, patients should begin protocol treatment within 10 days.* Issues that 
would cause treatment delays should be discussed with the Principal Investigator.  If a patient 
does not receive protocol therapy following registration, the patient’s registration on the study 
may be canceled.  The Study Coordinator should be  notified of cancellations as soon as possible.  
 
Except in very unusual circumstances, each participating institution will order DCTD -supplied 
agents directly from CTEP.  Agents may be ordered by a participating site only after the initial 
IRB approval for  the site has been forwarded by [CONTACT_36477] 
([EMAIL_617] ) except for Group studies.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
38 
 5.   TREATMENT PLAN  
 
Cycles are 21 days long. 5.1 Agent Administration  
Treatment will be administered on an outpatient  basis.  Reported adverse events and potential 
risks are described in Section 7.  Appropriate dose modifications are described in Section 6.  No 
investigational or commercial agents or therapi[INVESTIGATOR_798163]'s malignancy.  
 
AZD1775 Administration  
Oral AZD1775 will be given 300 mg once daily for 5 days a week for 2 weeks every cycle  (QD 
days 1 to 5 , and 8 to 12). One cycle of therapy will be 21 days: therefore, 10 doses each cycle. 
Dose escalation will not be permitted. Appropriate dose modifications and int erruptions will be 
allowed. O ther investigational or commercially available agents specificall y for cancer control 
will be prohibited. Patients will continue the treatment until they experience tumor progression, 
prohibitive toxicity or withdraw from the study by [CONTACT_1029].  
 
Table 3.  Regimen Description  
Agent  Premedications; Precautions * Schedule  Cycle Length  
AZD1775  5-HT3 antagonist (ondansetron 8 mg PO or 
granisetron 1 mg PO) prior to each dose of 
AZD1775;  
 
taken with 8 ounces of water approximately 
2 hours before or 2 hours after food  Days 1 -5,  
week 1  
Days 8 -12, 
week 2  21 days  
(3 weeks)  
 
 
 
*Dexamethasone (oral or intravenous) or the [ADDRESS_1100848] (intravenous) may be given for 
better symptom control as indicated. Prophylactic anti -emetic therapy with aprepi[INVESTIGATOR_798164].  
 
The patient will be requested to maintain a medication diary of each dose of medication.  The 
medication diary will be returned to clinic staff at the end of each course.  
 
AZD1775 should be taken with 8 ounces of water approximately 2 hours before or 2 hours after 
food. If a patient misses the daily dose according to the schedule, the dose should be taken as 
soon as possible, but not more than 12 hours after the missed dose was scheduled. If greater than 
12 hours, the missed dose should be skipped and the patient should take t he next dose when 
scheduled. If vomiting occurs after a patient takes the AZD1775 dose, the patient should be 
instructed not to retake the dose, but to wait until the next scheduled dose of AZD1775.  If no 
dose is  scheduled for the following day, the dose will not be ‘made up’.  If vomiting persists, the 
patient should contact [CONTACT_737].  
 
2.7 5.2 Study Procedures  
 
All patients will be evaluated and study procedur es will be performed in Figure 1 . Dosing, 
laboratory tests, imaging studies, and office visits will occur per protocol (within ± 4 days) 
unless patients’ medical or logistical issues necessitate adjustment.  
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
39 
 Pretreatment Evaluations  
To be completed within 4 weeks before initiation of therapy:  
• Medical history, including list of current medicat ions 
• Tumor markers, if applicable  
• Imaging studies, as appropriate for specific types of cancers  
• ECG and ECHO or MUGA, and then as clinically indicated  
• Mandatory biopsy  
• Urinalysis, to be repeated as clinically indicated  
• For women of childbearing potential , blood or urine pregnancy test at baseline and then 
periodically as clinically indicated  
• Obtainment of the informed consent document  
 
To be completed within 7 days before initiation of therapy:  
• Physical examination  
• ECOG performance status determination  
• Complete blood count with leukocyte differential and platelet count  
• Serum chemistry analysis, including sodium, potassium, chloride, carbon dioxide, BUN, 
creatinine, glucose, calcium, magnesium, albumin, alkaline phosphatase, total bilirubin,  
ALT, TSH, and free T [ADDRESS_1100849] cycle and then as clinically indicated:  
• Complete blood count and leukocyte differential and platelet count  
• Serum chemistry, including sodium, potassium, chloride, carbon dioxide, BUN, creatinine, 
glucose, calcium, magnesium, albumin, alkaline phosphatase, total bilirubin, AST, and ALT  
 
To be obtained once in every cycle of therapy (once every 3 weeks):  
• Medical history and physical examination  
• ECOG performance status  
• Asses sment of treatment -related and treatment -unrelated toxic effects  
• Complete blood count with leukocyte differential and platelet count  
• Serum chemistry, including sodium, potassium, chloride, carbon dioxide, BUN, creatinine, 
glucose, calcium, magnesium, album in, alkaline phosphatase, total bilirubin, AST and ALT  
 
To be obtained for tumor responses:  
• Evaluation of the tumor: the same imaging technique used during the initial evaluation or 
more sophisticated studies will be performed about once every 9 weeks ± 7 days  for six 
months , then once every 12 weeks ± 7 days, or sooner if clinically indicated  
• Tumor markers, if applicable, once with each imaging study, or more frequently as indicated  
 
 
Sample Collection for Correlative Studies  
Correlative studies will be performed by  [INVESTIGATOR_124]. Robert Kinders at the NCI-Frederick National 
Laboratory for Cance r Research,  Dr. K. Keyomarsi, in the Department of Experimental 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100850]. F. Meric -Bernstam in the Department of Investigational Cancer 
Therapeutics. Patients who experience  CR/PR will be encouraged to enroll into the Unusual 
Responders p rotocol (F. Meric -Bernstam) at MD Anderson.  
 
Blood Sample Collections:  
After the informed consent is obtained, blood sample s (~10 mL each) will be obtained at each of 
the following time -points:  
 
1. Prior to the initiation of treatment (pre -study), and cycle 1 day 8 (C1D8)  
2. Prior to the initiation of cycle 2 (C2D1) and cycle 2 day 8 (C2D8)  
3. At the end of the study, if available  
 
 
Tumor Sample Collections:  
After informed consent is obtained, tumor samples will be collected as follows:  
1. Ten 5 µm-thick FFPE slides, or tumor block – all patients  if available  
2. Pre-treatment core biopsy – mandatory for all patients  
3. Tumor core biopsy on C1D10 at 4 hours (± 2 hours) post dose– mandatory for all patients if 
clinically feasible  
4. Tumor core biopsy at relapse  – optional  for all patients .  
The time of drug administration and the time of biopsy will be documented.  
 
 Please refer to Section 9 and Appendix D for more details.  
 
 
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100851] be recorded in the appropriate sections of the CRF.  
 
Mandatory prophylactic anti -emetics will be required for al l patients . Treatment with the anti -
emetics aprepi[INVESTIGATOR_053] [Emend] and fosaprepi[INVESTIGATOR_798165] -drug 
interactions . In addition, loperamide (Imodium) is required at the first onset of diarrhea 
according to  ASCO guideline s. Oral loperamide (Imodium) 4mg should be administered at the 
first onset of diarrhea and then 2mg every [ADDRESS_1100852] dose of loperamide could be lowered to 2mg if the diarrhea is recurrent and if, in the opi[INVESTIGATOR_379164], the diarrhea is not severe.  
Medications may be administered for maintenance of existing conditions prior to study  
enrol lment or for a new condition that develops while on study, including but not limited to the  
following:  
 
•   Bisphosphonates and receptor activator of nuclear factor kappa -B ligand (RANKL)  
inhibitors (e.g. denosumab).  
•   Patients requiring therapeutic warfarin or coumarin -derivative anticoagulants will be 
monitored with international normalized ratio (INR) and pro thrombin time (PT) as clinically 
indicated.  
•   Low molecular weight heparin (LMWH), rivaroxaban, or equivalent anticoagulant  therapy is 
permitted where clinically indicated.  
•   Patients may receive treatment with megestrol acetate when prescribed for appetit e 
stimulation.  
  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100853].  Additional restrictions may be included depending on individual study requirements.  
 
• AZD1775 should be  taken with 8 ounces of water approximately 2 hours before or 2 hours 
after food.  
• In once a day dosing if a patient misses the daily dose according to the schedule, the dose 
should be taken as soon as possible, but not more than 12 hours after the missed dose was 
scheduled. If greater than 12 hours, the missed dose should be skipped and the patient should 
take the next dose when scheduled  
• If vomiting occurs after a patient takes the AZD1775 dose, the patient should be instructed 
not to retake the dose, but  to wait until the next scheduled dose of AZD1775.  If no dose is  
scheduled for the following day, the dose will not be ‘made up’.  If vomiting persists, the 
patient should contact [CONTACT_737].  
• Women of childbearing potential (WoCBP) may be included o nly if acceptable  contraception 
is in place for two weeks before study entry, for the duration of the  treatment with the study 
drug and for [ADDRESS_1100854] dose of AZD1775  
• WoCBP defined as: Women between menarche and menopause who have not been  
permanently or surgically sterilized and are capable of procreation.  
• All WoCBP must have a negative pregnancy test within 3 days prior to study entry  and prior 
to starting each treatment cycle.  
• Male  patient s who are involved in the study must agree to avoid p rocreative and unprotected 
sex and must  not donate sperm during the study and for [ADDRESS_1100855] dose  of 
AZD1775.  
• Female partners, who are of child -bearing potential, of men participating in clinical studies of 
AZD1775 will also be required to use effective contraceptive measures (detailed in Appendix 
D) while their partner is on study drug and for 3 months thereafter.  
• Male patients will be advised to arrange for the freezing  of sperm samples prior to the start of 
the study should they wish to father children while on  AZD1775 or during the 3 mo nths after 
stoppi[INVESTIGATOR_798166]1775.   
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
43 
 Prohibited concomitant medications  
 
The following treatments and the medications listed in Appendix D are prohibited or should be 
used with caution while in AZD1775 studies.  Any further questions regarding concomitant 
treatments should be referred to a Medical Monitor.  
• No formal clinical drug interaction studies have been performed with AZD1775. An 
explo ratory assessment of the effect of aprepi[INVESTIGATOR_173321]1775 exposure in oncology 
patients suggests that there is a drug interaction between AZD1775 and aprepi[INVESTIGATOR_053], as 
exposure to AZD1775 increased by ~60% when aprepi[INVESTIGATOR_173322] -administered with 
AZD1775. The observed increase in AZD1775 exposure is likely the result of CYP3A4 
inhibition by [CONTACT_173369][INVESTIGATOR_053]. This increase in exposure is statistically significant. At the 
selected MTDs, this increase may also be of clinical importance. Therefore, concomitant 
treatment with aprepi[INVESTIGATOR_798167].   
 
Potent or moderate inhibitors or inducers of CYP3A4, sensitive CYP3A4 substrates, and 
CYP3A4 substrates with a narrow therapeutic window should be avoided until ad ditional 
data on drug -drug interactions (DDI) becomes available. The use of sensitive substrates 
of CYP3A4, such as atorvastatin, simvastatin and lovastatin, is prohibited in this study. 
As grapefruit and Seville oranges are known to contain moderate inhib itors of CYP3A4, 
these fruits or their products (including marmalade, juice, etc.) should be avoided while 
taking AZD1775.  
 
• In vitro data suggests that AZD1775 may also be a weak reversible inhibitor of 
CYP2C19.  Caution should be exercised with concomitan t administration of AZD1775 
and agents that are sensitive substrates of CYP2C19, or substrates of this enzyme with 
narrow therapeutic range; refer to Appendix D for a list of sensitive substrates of 
CYP2C19, or substrates of this enzyme with narrow therape utic range.  
 
• AZD1775 has been shown to be a weak inducer of CYP1A2 in vitro with a maximum 
measured response between donors of 39.9% to 93.1% (at 10 μM) and 18.6% to 32.5% 
(at 5 μM) of the positive control omeprazole (50 μM). Given the nature of the AZD177 5 
dosing schedule, however, the risk of induction in the clinic is considered low. No 
specific precautions are recommended at this time, except to be initially vigilant when 
using substrates of CYP1A2 with a narrow therapeutic range.  
 
• In vitro studies have  shown that AZD1775 may be a substrate and inhibitor for human P -
glycoprotein (P -gp). Caution should be exercised when agents that are inhibitors or 
substrates of P -gp are administered concomitantly with AZD1775 (see Appendix D). 
 
• in vitro  transporter studies have shown AZD1775 to be an inhibitor of BCRP (IC50 5.1 
μM). This finding is particularly relevant for drugs administered orally where exposure is 
normally limited by [CONTACT_69811] -mediated efflux, in particular some statins, such as 
rosuvastat in. Other drugs where the disposition is mediated via BCRP should be 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
44 
 administered with caution, dose modification considered or substituted by [CONTACT_710464].  
 
• Metformin should be used with caution. AZD1775 has been shown to be an inhibitor of 
MATE1 a nd MATE2K transporters. A drug interaction with substrates of either 
transporter cannot be ruled out, the most important substrate known to date being 
metformin.  
 
• Herbal preparations/medications are not allowed throughout the study. These herbal 
medication s include, but are not limited to: St. John’s wort, kava, ephedra (ma huang), 
gingko biloba, dehydroepi[INVESTIGATOR_2119] (DHEA), yohimbe, saw palmetto, and ginseng. 
Patients should stop using these herbal medications [ADDRESS_1100856] dose of 
AZD1775.  
 
2.10 5.5 Duration of Therapy  
 
In the absence of treatment delays due to adverse event (s), treatment may continue or until one 
of the following criteria applies:  
 
•  Disease progression  
 
•  Intercurrent illness that prevents further administration of treatment  
 
•  Unacceptable adverse event(s)  
 
•  Patient decides to withdraw from the study  
 
•  General or specific changes in the patient's condition render the patient unacceptable for 
further treatment in the judgment of the investigator  
 
•  Clinical progression  
 
•  Patient non -compliance  
 
•  Pregnancy  
 
All women of child bearing potential should be instructed to contact [CONTACT_278611] (e.g., missed or late menstrual period) at 
any time during study participation.  
 
The investigator must immediately notify CTEP in the event of a confirmed pregnancy in a 
patient participating in the study.  
 
• Termination of the study by [CONTACT_798204] #: [ZIP_CODE]  
Version Date:  2 June 2020  
45 
 • The drug manufacturer can no longer provide the study agent  
 
The reason(s) for protocol therapy d iscontinuation , the reason(s) for  study removal , and the 
corresponding dates must be documented in the Case Report Form (CRF).  A patient that decides 
to discontinue investigational product (IP) should be asked about the  reason(s) and the 
occurrence of any AEs.  
   
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
46 
 2.11 5.6 Duration of Follow Up  
 
•   Patients will be followed for [ADDRESS_1100857].  
 
•   Patients who discontinue the study treatment for reasons other than disease progression, will 
continue to undergo radiographic tumor assessment until radiographic documentation of disease 
progression every [ADDRESS_1100858].  
 
•   Patients who d iscontinue the study treatment for unacceptable adverse event(s) will be 
followed until resolution or stabilization of the adverse event, or until radiographic 
documentation  
 
  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100859] 
immediately notify the Principal Investigator, Siqing Fu, MD, PhD at 713 -404-1141 (Pager).  
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
48 
 6.  DOSING DELAYS/DOSE MODIFICATIONS  
 
The principal investigator [INVESTIGATOR_397641]. 6.[ADDRESS_1100860].  An undesirable medical condition can 
be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver) or the abnormal 
results of an investigation (e.g., l aboratory findings, electrocardiogram).  In clinical studies, an 
AE can include an undesirable medical condition occurring at any time, including run -in or 
washout periods, even if no study treatment has been administered.  
 
The term AE is used to include both serious and non -serious AEs.  
 
 
 Definitions of serious adverse event  
 
A serious adverse event is an AE occurring during any study phase (i.e., run -in, treatment, 
washout, follow -up), that fulfils one or more of the following criteria:  
• Result s in death  
• Is immediately life -threatening  
• Requires in -patient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability/incapacity or substantial disruption of the ability 
to conduct normal life functions  
• Is a congenital abnormality or birth defect  
• Is an important medical event that may jeopardize the subject or may require medical 
intervention to prevent one of the outcomes listed above.  
 
The causality of SAEs (their relationship to all study treatment/pr ocedures) will be assessed by 
[CONTACT_093](s) and communicated to [COMPANY_008].  
 
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
49 
  Dose Modification  
 
Toxicity will be assessed utilizing the NCI CTCAE v5.0 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE), unless otherwise specified.  
 
Dose adjustments will be based on the organ system exhibiting the greatest degree of toxicity. 
Dose reductions or holds and initiation of supportive care are allowed as clinically indicated by 
[CONTACT_1963] . A maximum of 2 dose reductions for AZD1775 w ill be allowed. Patients 
requiring >[ADDRESS_1100861] be discontinued from the study unless there is approval from the 
Medical Monitor for the patient to continue.  
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
50 
 2.13  Dose modifications due to hematologic toxicity  
 
Complete blood counts (CBC) will be obtained for all patients at the beginning of each treatment 
cycle (Day 1).  If hematologic toxicity occurs (see Table 6 and Table 7), treatment should be held 
and ANC and platelets should be monitored weekly (or more oft en as clinically indicated) until 
recovery.  
 
Table 6:   Day 1 Hematologic Dose Modifications  
Treatment Day Blood Counts and Toxicity  
ANC   Platelets  Action  
≥1000/μL  And ≥75,000/μL  No dose modification or interruption  
<1000/μL  Or <75,000/μL  Delay by 1 week intervals until recovery  
 
If hematologic toxicity parameters do not recover within 21 days, the patient should be 
removed from the study treatment.   
 
 
Table 7:   Neutropenia, Infection, Febrile Neutropenia Dose Modifications and Management  
Any Day   
Grade 3 neutropenic fever  (ANC <1000/µL + Temperature 
≥101°F [38.5°C]) or neutropenic infection  
Documented infection with Grade 3 neutropenia  (ANC 
<1000/µL)  
Grade 4 neutropenia  
(ANC <500/μL >7 days  
Grade 4 thrombocytopenia  (platelet count <25,000/μL >7 days)  Hold dose until recovery.   
Then, upon resuming dosing, 
reduce AZD1775 to the next 
lower dose levela.   
 
Grade 4 febrile neutropenia or Grade 4 infection with 
neutropenia  (both defined as septic shock)  
Thrombocytopenic haemorrhage  (gross occult bleeding) 
associated with a platelet count <50,000/μL  Discontinue treatment is 
recommended,  and follow for 
disease progression.  
However patient may continue 
after dose reductions on ly when 
treating physician, the study 
chair and the patient concur.  
 
a No more than two dose reductions will be allowed for any patient.  Patients requiring additional 
dose modifications due to toxicity will discontinue study treatment.  
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100862], as appropriate. Dose reductions or holds and initiation of 
supportive care are allowed as clinically indicated by [CONTACT_798205].  
 
Dose reductions of  AZD1775 should be considered only if toxicity is consi dered to be related to 
AZD1775 . Dose re -escalation is not permitted.  
 
In general, if a patient experiences a G rade 1 / Grade 2 non -hematological toxicity, no dose 
modification is required (except QTc prolongation, see Table 8in ). If a patient experiences a G3 
or G4 toxicity which is not attributable to the disease or disease related processes under 
investigation, dosing will be interrupted and/or the dose reduced and supportive therapy 
administered as  required.  Any patient who develops a Grade 3 or 4 non -hematologic toxicity 
that does not resolve to ≤ Grade 1 within 21 days should be removed from the study treatment 
unless approved by [CONTACT_1689].   
 
 
Dose modification for QTc interval prolongation  
Table 8:  AZD1775 dose modifications for QTc interval prolongation  
Electrocardiogram QT corrected interval prolonged  
QTc Value  AZD1775  
QTc 450 -480 ms (males) or 
470-480 (females)  Hold.   Once QTc interval has returned to pre -treatment 
status and correction of poss ible electrolyte imbalance has 
been made, resume at next lower dose level.  
QTc [ADDRESS_1100863] advice.  
QTc ≥ 501 ms  Discontinue treatment  
Shift from baseline of ≥ 60ms  Discontinue treatment  
 
 
Diarrhea  
Due to frequent reports of diarrhea with AZD1775 administration, vigorous anti -diarrheal 
treatment loperamide (Imodium) is required at the first onset of diarrhea according to American 
Society of Clinical Oncology (ASCO) guidelines. Oral loperamide (Imodiu m) [ADDRESS_1100864] dose of loperamide 
could be lowered to 2 mg if the diarrhea is recurrent and if, in the opi[INVESTIGATOR_33398], the diarrhea is not severe.   
 
Patients should be instructed to notify the Investigator or rese arch staff of the occurrence of 
bloody or black stools, symptoms of dehydration, fever, inability to take liquids by [CONTACT_1966], and 
inability to control diarrhea within 24 hours of using loperamide or  other prescribed antidiarrheal 
medications . 
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
52 
 If diarrhea is severe (i.e., requiring intravenous [IV] rehydration) and/or associated with fever or 
severe neutropenia (Grade 3 or 4), broad -spectrum antibiotics must be prescribed. Patients with 
severe diarrh ea or any diarrhea associated with severe nausea or vomiting should be hospi[INVESTIGATOR_798168].  Guidelines  for dose modification of 
AZD1775 will be considered as seen in Table 8.  
 
Table 9:  AZD1775 dose modifications for diarrhea  
Diarrhea  Management/Next Dose for AZD1775  
≤ Grade 1  No change in dose  
Grade 2  Hold until ≤ Grade 1.  Resume at same dose level.  
Grade 3  Hold* until ≤ Grade 1.  Resume at one dose level lower, if 
indicated.** 
Grade 4  Off protocol therapy  
*Patients requiring a delay of >2 weeks should go off protocol therapy.  
**Patients requiring > two dose reductions should go off protocol therapy.  
Recommended management:  Loperamide antidiarrheal therapy  
Dosage schedule:  [ADDRESS_1100865] onset, followed by 2 mg with each loose motion until 
diarrhea -free for 12 hours (maximum dosage:  16 mg/24 hours)  
Adjunct anti -diarrheal therapy is permitted and should be record ed when used.  
 
 
Nausea and vomiting (mandatory antiemetic prophylaxis)  
All patients must receive a [ADDRESS_1100866], ondansetron (Zofran) 8 mg PO QD or granisetron 
(Kytril ) [ADDRESS_1100867] may be given by [CONTACT_735886]. .   
 
Promethazine (Phenergan), prochlorperazine (Compazine), and benzodiazepi[INVESTIGATOR_798169]1775 therapy.    
 
Please note: apre pi[INVESTIGATOR_053] [Emend] and fosaprepi[INVESTIGATOR_798170].  
Patients should be strongly encouraged to maintain liberal oral fluid intake.  
 
 
Suitable alternative medications may be used, with adequate justification, in those studies where 
the use of any of the above medications might interfere with other study procedures or are 
deemed insufficient.  Guidelines for dose modification of AZD1775 will be considered for 
nausea and vomiting as seen in Table 9 and Table 10, respectively.  
 
Table 10:  AZD1775 dose modifications for nausea  
Nausea  Management/Next Dose for AZD1775  
≤ Grade 1  No change in dose  
Grade 2  Hold until ≤ Grade 1.  Resume at same dose level.  
Grade 3  Hold* until ≤Grade 1.  Resume at one dose level lower, if indicated.** 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
53 
 Table 10:  AZD1775 dose modifications for nausea  
Nausea  Management/Next Dose for AZD1775  
Grade 4  Off protocol therapy  
*Patients requiring a delay of >2 weeks should go off protocol therapy.  
**Patients requiring > two dose reductions should go off protocol therapy.  
Recommended management:  antiemetics.  
 
 
Table 11:  AZD1775 dose modifications for vomiting  
Vomiting  Management/Next Dose for AZD1775  
≤ Grade 1  No change in dose  
Grade 2  Hold until ≤ Grade 1.  Resume at same dose level.  
Grade 3  Hold* until ≤ Grade 1.  Resume at one dose level lower, if indicated.** 
Grade 4  Off protocol therapy  
*Patients requiring a delay of >2 weeks should go off protocol therapy.  
**Patients requiring > two dose reductions should go off protocol therapy.  
Recommended management:  antiemetics.  
 
 
Febrile neutropenia  
Patients experiencing febrile neutropenia with significant symptoms should be managed in a  
hospi[INVESTIGATOR_598265], with the urgent initiation of IV antibiotic  
therapy. Patients with febrile neutropenia without symptoms should be managed according to  
standard guidelines.  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100868] administration.  
 
SAEs will be recorded from the time of informed c onsent and should be reported to CTEP .  
 
 
Follow -up of unresolved adverse events  
Any AEs that are unresolved at the patient’s last visit in the study are followed up by [CONTACT_149798], but without further recording in the eCRF.  
 
 
If an Investigator learns of any SAEs,  including death, at any time after a patient has completed 
the study and he/she considers there is a reasonable possibility that the event is related to 
AZD1775, the Investigator should notify CTEP . 
 
The following variables will be collected for each AE:  
• AE (verbatim)  
• The date and time  when the AE started and stopped  
• The maximum intensity or inte nsity or changes in intensity  
• CTCAE grade/max CTAE  grade/changes in CTCAE grade  
• Whether the AE is serious or not  
• Investigator causality rating against the Investigational Product (yes or no)  
• Action taken with regard to investigational product  
• AE caused  subject’s withdrawal from study (yes or no ) 
• Outcome.  
 
In addition, the following variables will be collected for SAEs:  
• Date AE met criteria for serious AE  
• Date Investigator became aware of serious AE  
• Reason AE is serious  
• Date of hospi[INVESTIGATOR_059]  
• Date of discharge  
• Probable cause of death  
• Date of death  
• Autopsy performed  
• Causality assessment in relation to Study procedure(s)  
• Causality assessment in relation to Other medication  
• Causality assessment in relation to module -specific combination treatments  
• Description of AE.  
 
The grading scales found i n the revised CTCAE Version 5.0 will be utilized for all events with 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
55 
 an assigned CTCAE grading. For those events without assigned CTCAE grades, the 
recommendation in the CTCAE criteria should be utilized that converts mild, moderate, and 
severe events. A copy of the current CTCAE version can be downloaded from the Cancer 
Therapy Evaluation Program website ( http://ctep.cancer.gov ). 
 
It is important to distinguish between serious and severe AEs.  Severity is a measure of intensity 
whereas seriousness is defined by [CONTACT_14540] 7.3.  An AE of severe intensity need not 
necessarily be considered serious.  For example, nausea that persists for several hours may be 
considered severe nausea, but not a SAE. On the other hand, a stroke that results in only a 
limited degree of disability may be considered a mild stroke but woul d be a SAE.  
 
 
Adverse Events based on signs and symptoms  
All AEs spontaneously reported by [CONTACT_102], reported in response to the open question from 
the study personnel, or revealed by [CONTACT_178557].  
 
When collect ing AEs, the recording of a diagnosis is preferred (when possible) to the recording 
of a list of signs and symptoms. However, if a diagnosis is known and there are other signs or 
symptoms that are not generally part of the diagnosis, the diagnosis and each  sign or symptom 
will be recorded separately.  
 
They do not include metastases of the original cancer.  
 
 
Adverse Events based on examinations and tests  
The results from protocol mandated laboratory tests and vital signs will be summarised in the 
CSR.  Deter ioration as compared to baseline in protocol -mandated laboratory values, vital signs 
and ECG should therefore only be reported as AEs if they fulfil any of the SAE criteria or are the 
reason for discontinuation of the study treatment unless clearly due to the progression of dis ease 
under study . 
 
If deterioration in a laboratory value/vital sign/ECG is associated with clinical signs and 
symptoms, the sign or symptom will be reported as an AE and the associated laboratory 
result/vital sign/ECG will be conside red as additional information. Wherever possible the 
reporting Investigator uses the clinical, rather tha n the laboratory term (e.g., an emia versus low 
hemoglobin value). In the absence of clinical signs or symptoms, clinically relevant 
deteriorations in n on-mandated parameters should be reported as AE(s).  
Deterioration of a laboratory value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.  
 
Any new or aggravated clinically relevant abnormal medical finding at a physic al examination as 
compared with the baseline assessment will be reported as an AE.  
 
Examples of th ese are marked h ematological  and other laboratory abnormalities, and certain 
events that lead to intervention (other than those already classified as serious), dose reduction or 
significant additional treatment.  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
56 
  
 
Hy’s Law  
Cases where a patient shows elevations in liver biochemistry may require further evaluation and 
occurrences of AST or ALT ≥[ADDRESS_1100869] together with total bilirubin ≥[ADDRESS_1100870]’s condition attributable to the 
disease for which the investigational product is being studied.  It may be an increase in the 
severity of the disease under study and/or increases in the symptoms of the disease.  (For 
example, the progression of existing metastasis to the primary cancer under study)  should be 
considered as disease progression and not an AE.  Events, which are unequivocally due to 
disease progression, should not be reported as an AE during the study.  
 
 
New cancers  
The development of a new cancer should be regarded as an AE and will generally meet at least 
one of the serious criteria. New cancers are those that are not the primary reason for the 
administration of the study treatment and have been identified after the patient’s inclusion in this 
study. They do not include metastases of the original cancer.  
 
Investigators must report SAEs and follow -up information to their responsible IRB according to 
the policies of the responsible IRB. For fatal or  life-threatening AEs where important or relevant 
information is missing, active follow -up is undertaken immediately.  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
57 
 Laboratory safety assessment  
Blood and samples for determination of clinical chemistry, haematology, coagulation, and P D 
will be perform ed at the times indicated in the Study Plan ( Table 12). 
 
Additional safety samples may be collected as clinically indicated and at the discretion of the 
Investigator. The date, time of collection and results (values, units and reference ranges) will be 
recorded on the appropriate eCRF.  
 
The clinical chemistry an d haematology will be performed at a CLIA -certified  laboratory . 
Sample tubes and sample sizes may vary depending on laboratory method used and routine 
practice at the study centre.  
 
The following laboratory variables will be measured as a minimum (some of these variables may 
be measured at baseline only):  
 
  Table 12:  Laboratory Safety Variables  
Hematology (2.7  mL whole blood 
sample)  Clinical chemistry (2.7  mL serum or 
plasma sample)  
B-Hemoglobin  S/P-Albumin  
B-Leukocyte  S/P-Alanine transaminase (ALT)  
B-Hematocrit  S/P-Aspartate transaminase (AST)  
B-Red blood cell count  S/P-Alkaline phosphatase (ALP)  
B-Absolute leukocyte differential count  S/P-Bilirubin, total  
Neutrophils  S/P-Calcium, total  
Lymphocytes  S/P-Creatinine  
Monocytes  S/P-Chloride   
S/P-Glucose  
S/P-Magnesium  
Basophils  S/P-Potassium   
Eosinophils  S/P-Sodium   
B-Platelet count  S/P-Urea nitrogen or blood urea nitrogen  
S/P-TSH  
Coagulation (1.8  mL sample)  S/P-Free T 4 
S/P-CO2  
S/P-BUN   
B-PT or INR with PTT   
Pregnancy test (Blood or urine)   
 
Pre-menopausal women of childbearing potential must have a negative urine or serum pregnancy 
test within [ADDRESS_1100871] to clinically 
relevant abnormalities. Any clinically significant abnormal laboratory values should be repeated 
as clinically indicated and recorded on the eCRF. The laboratory results should be signed and 
dated and retai ned at centre as source data for laboratory variables.  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100872] or ALT ≥[ADDRESS_1100873] (upper limit of normal) and total 
bilirubin ≥[ADDRESS_1100874] please refer to Appendix  D ‘Actions required in cases of combined increase 
of Aminotransferase and Total Bilirubin – Hy’s Law’, for further instructions.  
 
 
Physical examination  
A complete physical examination will be performed and include an assessment of the following: 
general appearance , respi[INVESTIGATOR_696], cardiovascular, abdomen,  skin, head  and neck (including ears, 
eyes, nose and throat), lymph nodes, thyroid, musculo -skeletal (including spi[INVESTIGATOR_98243]) 
and neurological systems.  
 
If new or aggravated physical findings imply deterioration compared with baseline, the finding 
should be reported as an AE . Performance status will be assessed using the ECOG performance 
status criter ia. 
 
 
ECG  
Resting 12 -lead ECG  
A triplicate 12-lead safety ECG (paper ECG printout of 10 seconds for Investigator review) will 
be taken at screening and prior to dosing of each study cycle , and as clinically indicated .  
 
At any other time the Investigator deems necessary for safety during the administration period, 
triplicate ECG recordings should be taken within an approximate [ADDRESS_1100875] be in the same supi[INVESTIGATOR_113050] (maximum [ADDRESS_1100876]) at the recording tim e point.  
 
The Investigator will judge the overall interpretation as normal or abnormal. If abnormal, it will 
be decided as to whether or not  the abnormality is clinically significant or not clinically 
significant. The paper copy of each ECG reading will be retained with the patient’s completed 
source documents. Only overall evaluation (normal/abnormal) will be recorded in the eCRF. If 
there is  a clinically significant abnormal unscheduled ECG finding during the treatment period, 
this should be recorded on the AE eCRF, according to standard AE collection and rep orting 
processes .  
 
Attention should be paid to any detected increases in QTc interva l. Patients who develop a single 
resting value of QTc interval of >450 msec/male and >470 msec/female or a shift from baseline 
of 60ms should stop taking AZD1775. Dosing can be resumed at a reduced dose (see section 
[IP_ADDRESS]) after return of the resting QTc  interval to pre -treatment status has been confirmed and 
correction of possible electrolyte imbalance has been made.  
 
Monitoring of QTc, checking and correction of abnormal electrolyte levels and renal function are 
advised, especially in case of severe/pro longed diarrhoea.  If QTc increases markedly from 
baseline, but stays below the above limits, a cardiologist’s advice should be sought.  
 
The concomitant use of ondansetron (known to prolong the QTc interval in rare cases, per 
labelling) should be taken int o account when interpreting QTc changes.  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
59 
  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
60 
 7.   ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of AEs (Section 7.1) and the characteristics of an o bserved AE (Section 7.2  and 
7.3) will determine whether the event requires expedited  reporting via the CTEP Adverse Event 
Reporting System (CTEP -AERS ) in addition  to routine  reporting.  
 
 
7.[ADDRESS_1100877] ( CAEPRs)  
 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform 
presentation of events by [CONTACT_6764].  In addition to the comprehens ive list, a subset  of AEs , 
the Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column 
and is identified with bold and italicized text.  Th e SPEER is a list of events that are protocol -
specific exceptions to expedited repo rting to NCI (except as noted below).  Refer to the 'CTEP, 
NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm  for further clarification.  
 
NOTE :  The highest grade curr ently reported is noted in parentheses next to the AE in the 
SPEER.   Report ONLY AEs higher than this grade expeditiously.  If this CAEPR is part of a 
combination protocol  using multiple inv estigational agents and has an AE listed on different 
SPEERs, use the lower of the grades to determine if expedited reporting is required.  
 
7.1.[ADDRESS_1100878] (CAEPR)  for AZD1775 
(adavosertib, NSC 751084)  
 
 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of reported and/or 
potential adverse events (AE) associated with an agent using a uniform presentation of events by [CONTACT_6764]. In 
addition to the comprehensive list,  a subset, the Specific Protocol Exceptions to Expedited Reporting (SPEER), 
appears in a separate column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of 
events that are protocol specific exceptions to expedited repo rting to NCI (except as noted below).  Refer to the 
'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelop ment/electronic_applications/docs/aeguidelines.pdf  for further clarification. 
Frequency is provided based on 323 patients. Below is the CAEPR for AZD1775 (adavosertib).  
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses next t o the AE in the 
SPEER.  If this CAEPR is part of a combination protocol using multiple investigational agents and has an AE 
listed on different SPEERs, use the lower of the grades to determine if expedited reporting is required.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
61 
 Table 13: CAEPR for AZD1 775 ( Adavosertib , NSC 751084)  
 
Version 2.7, April 27, [ZIP_CODE] 
 
 Adverse Events with Possib le  
 Relationship to AZD1775 (adavosertib)  
 (CTCAE 5.0 Term)  
[n= 323]   
 
 Specific Protocol Exceptions 
to Expedited Reporting  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
 Anemia    Anemia (Gr 3)  
  Febrile neutropenia    
CARDIAC DISORDERS    
  Atrial fibrillation    
  Supraventricular tachycardia    
GASTROINTESTINAL DISORDERS    
 Abdominal pain    Abdominal pain (Gr 2)  
 Constipation    Constipation (Gr 2)  
Diarrhea     Diarrhea (Gr 3)  
 Dyspepsia     
  Gastrointestinal hemorrhage2   
 Mucositis oral    Mucositis oral (Gr 2)  
Nausea     Nausea (Gr 3)  
Vomiting     Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
 Edema limbs    Edema limbs (Gr 2)  
Fatigue     Fatigue (Gr  3) 
 Fever    Fever (Gr 2)  
HEPATOBILIARY DISORDERS    
  Hepatobiliary disorders - Other 
(hepatitis)    
INFECTIONS AND INFESTATIONS    
 Infection3   Infection3 (Gr 3)  
INVESTIGATIONS    
 Alanine aminotransferase increased    Alanine aminotransferase 
increased (Gr 3)  
  Electrocardiogram QT corrected 
interval prolonged    
 Lymphocyte count decreased     
 Neutrophil count decreased    Neutrophil count decreased (Gr 4)  
 Platelet count decreased    Platelet count decreased (Gr 4)  
 Weight loss     
 White blood cell decreased    White blood cell decreased (Gr 4)  
METABOLISM AND NUTRITION DISORDERS    
 Anorexia    Anorexia (Gr 2)  
 Dehydration     
 Hypokalemia    Hypokalemia (Gr 2)  
 Hypomagnesemia    Hypomagnesemia (Gr 2)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Back pain    Back pain (Gr 2)  
 Muscle cramp     
 Myalgia    Myalgia (Gr 2)  
NERVOUS SYSTEM DISORDERS    
` Dizziness    Dizziness (Gr 2)  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
62 
  
 Adverse Events with Possib le  
 Relationship to AZD1775 (adavosertib)  
 (CTCAE 5.0 Term)  
[n= 323]   
 
 Specific Protocol Exceptions 
to Expedited Reporting  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
 Headache    Headache (Gr 2)  
  Intracranial hemorrhage    
PSYCHIATRIC DISORDERS    
 Insomnia     
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS    
 Cough    Cough (Gr 2)  
 Dyspnea    Dyspnea (Gr 2) 
  Hypoxia    
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
 Rash4   Rash4 (Gr 2)  
VASCULAR DISORDERS    
  Phlebitis    
 
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all Principal 
Investigators at the time of revision.  The current version can be obtained by [CONTACT_13172] 
[EMAIL_412] .  Your name, the name [CONTACT_6823], the protocol and the agent should be 
included in the e -mail.  
 
2Gastrointestinal hemorrhage includes Anal hemorrhage, Cecal hemorrhage, Colonic hemorrhage, Duodenal 
hemorrhage, Esophageal hemor rhage, Esophageal varices hemorrhage, Gastric hemorrhage, Hemorrhoidal 
hemorrhage, Ileal hemorrhage, Intra -abdominal hemorrhage, Jejunal hemorrhage, Lower gastrointestinal 
hemorrhage, Oral hemorrhage, Pancreatic hemorrhage, Rectal hemorrhage, Retroperitone al hemorrhage, and Upper 
gastrointestinal hemorrhage under the GASTROINTESTINAL DISORDERS SOC.  
 
3Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC.  
 
4Rash may include rash, erythema, eczema, and rash maculo -papular.  
 
5Peripheral neuropathy includes both peripheral motor neuropathy and peripheral sensory neuropathy.  
 
6Acute kidney injury includes renal impairment and acute renal insufficiency.  
 
 
 
Adverse events reported on AZD1775 (adavosertib ) trials, but for which there is insufficient evidence to 
suggest that there was a reasonable possibility that AZD1775 (adavosertib)  caused the adverse event:  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Blood and lymphatic system disorders - Other 
(pancytopeni a); Blood and lymphatic system disorders - Other (thrombocytosis); Blood and lymphatic system 
disorders - Other (right leg deep vein thrombosis); Leukocytosis  
Cardiac disorders  - Cardiac disorders - Other (cardiomegaly); Chest pain - cardiac; Myocardial in farction; 
Palpi[INVESTIGATOR_814]; Sinus bradycardia; Sinus tachycardia  
EAR AND LABY[CONTACT_33993]  - Ear pain; Hearing impaired; Tinnitus  
EYE DISORDERS  - Blurred vision; Cataract; Eye disorders - Other (eye swelling); Eye pain; Keratitis; 
Photophobia; Scleral disord er; Vision decreased; Watering eyes  
GASTROINTESTINAL DISORDERS  - Abdominal distension; Anal pain; Ascites; Belching; Bloating; Cheilitis; 
Colitis; Colonic obstruction; Dry mouth; Duodenal ulcer; Dysphagia; Enterocolitis; Flatulence; Gastric ulcer; 
Gastriti s; Hemorrhoids; Oral pain; Rectal pain; Small intestinal obstruction  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
63 
 GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Chills; Death NOS; Edema trunk; 
Flu like symptoms; Gait disturbance; General disorders and administration site conditions - Other (c atheter site 
pain); Infusion site extravasation; Malaise; Non -cardiac chest pain; Pain  
IMMUNE SYSTEM DISORDERS  - Allergic reaction; Anaphylaxis; Cytokine release syndrome  
INJURY, POISONING AND PROCEDURAL COMPLICATIONS  - Fall; Injury, poisoning and procedur al 
complications - Other (excoriation); Injury, poisoning and procedural complications - Other (ligament sprain)  
INVESTIGATIONS  - Alkaline phosphatase increased; Aspartate aminotransferase increased; Blood bilirubin 
increased; Creatinine increased; GGT inc reased; Investigations - Other (blood urea increased); Lymphocyte count 
increased  
METABOLISM AND NUTRITION DISORDERS  - Alkalosis; Hypercalcemia; Hyperglycemia; Hyperkalemia; 
Hyperuricemia; Hypoalbuminemia; Hypocalcemia; Hyponatremia; Hypophosphatemia; Tumo r lysis syndrome  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  - Arthralgia; Arthritis; Bone pain; Flank 
pain; Generalized muscle weakness; Muscle weakness lower limb; Musculoskeletal and connective tissue disorder - 
Other (groin pain); Neck pain; Pain i n extremity  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  - Neoplasms 
benign, malignant and unspecified (incl cysts and polyps) - Other (carcinoid tumor); Tumor pain  
NERVOUS SYSTEM DISORDERS  - Central nervous system necrosis; Cognitiv e disturbance; Depressed level of 
consciousness; Dysesthesia; Dysgeusia; Encephalopathy; Lethargy; Nervous system disorders - Other (hemiparesis); 
Paresthesia; Peripheral neuropathy5; Presyncope; Somnolence; Syncope  
PSYCHIATRIC DISORDERS  - Agitation; Anxiety; Confusion; Depression  
RENAL AND URINARY DISORDERS  - Acute kidney injury6; Hematuria; Urinary frequency; Urinary 
incontinence; Urinary retention; Urinary tract pain  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Genital edema; Reproductive system and breast 
disorders - Other (female genital tract fistula)  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  - Allergic rhinitis; Apnea; 
Bronchopulmonary hemorrhage; Epi[INVESTIGATOR_3940]; Hiccups; Nasal congestion; Pleural effusion; Pn eumonitis; Pulmonary 
hypertension; Respi[INVESTIGATOR_696], thoracic and mediastinal disorders - Other (diaphragmalgia); Voice alteration; Wheezing  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Alopecia; Bullous dermatitis; Dry skin; Hyperhidrosis; 
Pain of skin; Palmar -plantar erythrodysesthesia syndrome; Pruritus; Purpura; Rash acneiform; Skin ulceration; 
Urticaria  
VASCULAR DISORDERS  - Flushing; Hematoma; Hot flashes; Hypertension; Hypotension; Thromboembolic 
event  
 
 
 
Note : AZD1775 (adavosertib) in combination with other a gents could cause an exacerbation of any adverse event 
currently known to be caused by [CONTACT_6767], or the combination may result in events never previously 
associated with either agent.  
 
7.2   Adverse Event Characteristics  
 
•  CTCAE term (AE description) and grade:  The descriptions and grading scales found in the 
revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.[ADDRESS_1100879] access t o a copy of the 
CTCAE version 5.0.  A copy of the CTCAE version 5.0 can be downloaded from the CTEP web 
site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
•  For expedited reporting purposes only:   
− AEs for the AZD1775  that are bold and italicized  in the CAEPR ( i.e., those listed in the 
SPEER column, Section 7.1 ) should be reported through CTEP -AERS only if the grade is 
above the grade provided in the SPEER . 
− Other AEs for the NCI Protocol  #: [ZIP_CODE] that do not require expedited reporting are 
outline d in section 7.3.  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
64 
  
•  Attribution  of the AE:  
− Definite – The AE is clearly related  to the study treatment.  
− Probable – The AE is likely related to the study treatment.  
− Possible – The AE may be related  to the study treatment.  
− Unlikely – The AE is doubtfully related to the study treatment.  
− Unrelated – The AE is clearly NOT related  to the study treatment.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100880] use CTEP -AERS  (CTEP Adverse Event Reporting  
System), accessed via the CTEP Web site  (https://eapps -ctep.nci.nih.gov/ctepaers ).  The 
reporting procedures to be followed are presented in the “ NCI G uidelines  for Investigators:  
Adverse  Event Reporting Requirements  for DCTD (CTEP and CIP) and DCP INDs and IDEs ” 
which can be downloaded from the CTEP Web site  
(http://ctep.cancer.gov/protocolDevelopmen t/electronic_applications/adverse_events.htm ).  
These requirements are briefly outlined in the table s below ( Table 1 4). 
 
In the rare occurrence when Internet connectivity is lost, a 24-hour notification is to be made to 
CTEP by [CONTACT_1381] [PHONE_101] .  Once Internet connectivity is restored, the 24-hour 
notification phoned in must be entered electronically into CTEP -AERS  by [CONTACT_110697].  
 
 
Distribution of Adverse Event Reports  
 
CTEP -AERS  is programmed for automatic electronic distribution of reports to the following 
individuals:  Principal Investigator [INVESTIGATOR_33952] (s) (if applicable) of the 
Corresponding  Organization  or Lead Organization , the local treating physician, and the Reporter 
and Submitter .  CTEP -AERS  provides a copy feature for other e -mail recipi[INVESTIGATOR_840].  
 
The Coordinating Center of the Corresponding Organization is responsible for submitting to the 
CTSU documentation of AEs that they deem reportable for posting on the CTSU protocol web page 
and inclusion on the CTSU bi -monthly broadcast.  
 
 
Expedited Reporting Guidelines  
 
Use the NCI protocol number and the protocol -specific patient ID assigned during trial 
registration on all reports  (Table 1 4). 
 
Note:  A death on s tudy requires both  routine and expedited reporting , regardless of 
causality.  Attribution to treatment or other cause must be provided.  
 
Death due to progressive disease should be reported as Grade 5 “Neoplasms benign, malignant 
and unspecified (incl cysts and polyps) - Other (Progressive Disease)”  under the system 
organ class (SOC) of the same name.  Evidence that the death was a manifestation of underlying 
disease ( e.g., radiological changes suggesting tumor growth or progression: clinical deteriorat ion 
associated with a disease process) should be submitted.   
 
Table 14: Expedited Reporting Requirements for Adverse Events that Occur on Studies under an 
IND/IDE within [ADDRESS_1100881] Administration of the Investigational Agent/Intervention 1, 2 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
66 
 FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
 
NOTE:   Investigators MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not 
they are considered related to the investigational agent(s)/intervention ( 21 CFR 312.64)  
An adverse event is considered serious if it results in ANY  of the following outcomes:   
1) Death  
2) A life -threatening adverse event  
3) An adverse event that results in inpatient hospi[INVESTIGATOR_1328] ≥ 24 hours  
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospit alization may 
be considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may 
require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 
312.32; ICH E2A and IC H E6).  
 
ALL SERIOUS  adverse events that meet the above criteria MUST be immediately reported to the NCI via  electronic 
submission wi thin the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_317] 1 and Grade 2 Timeframes  Grade 3 -5 
Timeframes  
Resulting in Hospi[INVESTIGATOR_059] ≥ 24 hrs  10 Calendar Days  
24-Hour 5 Calendar Days  
Not resulting in Hospi[INVESTIGATOR_059] ≥ 24 hrs  Not required  
NOTE:   Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific 
Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR.  
 
Expedited AE reporting timelines are defined as:  
o “24-Hour; 5 Calendar Days” - The A E must initially be submitted electronically within  24 hours of learning of the 
AE, followed by a complete expedited report within 5 calendar days of the initial 24 -hour report.  
o “10 Calendar Days” - A complete expedited report on the AE must be submitted electronically within [ADDRESS_1100882] administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24 -hour notification followed by [CONTACT_6794] 5 calendar days for:  
• All Grade 3, 4, and Grade 5 AEs  
Expedited 10 calendar day reports for:  
Grade [ADDRESS_1100883] whole day, after the agent/intervention was last administered.  Footnote “1” above  
applies after this reporting period.  
 
Effective Date:  May 5, 2011  
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100884].  
 
 
7.5   Secondary Malignancy  
 
A secondary malignancy is a cancer caused by [CONTACT_437] a previous malignancy ( e.g., 
treatment with investigational agent/intervention, radiation or chemotherapy). A secondary 
malignancy is not considered a meta stasis of the initial neoplasm.  
 
CTEP requires all secondary maligna ncies that occur following treatment with an agent under an 
NCI IND/IDE be reported  expeditiously  via CTEP -AERS .  Three options are available to 
describe the event:  
 
•  Leukemia secondary to oncology chemotherapy ( e.g., acute myelocytic leukemia [AML])  
•  Myelodysplastic syndrome (MDS)  
•  Treatment -related secondary malignancy  
 
Any malignancy possibly related to cancer treatment (including AML/MDS) should also be 
reported via the routine reporting mechanisms outlined in each protocol.  
 
Indicate form for reporting in Rave, timeframes, and if loading of the pathology report is 
required.  
 
7.6   Second Malignancy  
 
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a 
metastasis from the initia l malignancy).  Second malignancies require ONLY routine AE 
reporting unless otherwise specified . 
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100885] of the adverse events and potential risks associated with the investigational agent  
administered in this s tudy can be f ound in Section 7 . 
 
8.1   AZD1775 (NSC # 751084 ) 
 
Chemical Name:  2-allyl-1-[6-(1-hydroxy -1-methylethyl)pyridin -2-yl]-6-([4-(4-methylpi[INVESTIGATOR_9482] -
1-yl)phenyl]amino) -1,2-dihydro -3H-pyrazolo[3,4 -d]pyrimidin -3- one 
 
Classification : Inhibitor of  Wee1 -kinase  
 
CAS : 955365 -80-7 
 
Molecular Formula:  C27H32N8O2·H2O M.W.:  518.623  
 
 
Mode of Action : AZD1775 is an inhibitor of the Wee1 -kinase. Wee1 is  a tyrosine kinase 
upstream of CDC2 thereby [CONTACT_798206], particularly the G2 
checkpoint. As the majority of human cancers  harbor abnormalities in the p53 pathway they 
become more dependent on S - and G2-phase checkpoints. In preclinical models, AZD1775 
selectively  enhanced  chemotherapy -induced death of cells deficient in p53  signaling.  
Description: AZD1775 is a crystalline, non -hygroscopic, monohydrate of  the neutral drug.  It 
dehydrates upon heating leading to formation of a crystalline  anhydrate.  
 
How Supplied: AZD1775 is supplied by [CONTACT_798207], CTEP/DCTD/NCI as capsules available in 25 mg (yellow color, size 2 
gelatin capsule) and 100 mg (orange color, size 2 gelatin capsule) strengths.  The dry -filled 
capsules consist of a roller -compacted granule of drug substance, lactose monohydrate, 
microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.  Each high -density 
polyet hylene (HDPE) bottle contains [ADDRESS_1100886] stability data to support repackaging AZD1775 
capsules in any container other than what is provided.  
 
Storage:   
Store at 2 to 30˚C (36 to 86˚F).  Do not freeze.  
 
If a storage temperature excursion is identified, promptly return AZD1775 to between 2 -30°C and 
quarantine the supplies.  Provide a detailed report of the excursion (including documentation of 
temperature monitoring and duration of the excursion) to [EMAIL_087]  for 
determination of suitability.  
Stability:  Shelf life studies of AZD1775 are  on-going.  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
69 
  
Route of Administration: Oral administration. Take AZD1775 at least two hours before or two 
hours after a meal.  
 
Potential Drug Interactions : AZD1775 is primarily metabolized by  [CONTACT_097]3A4 and is a weak, 
time-dependent inhibitor of CYP3A4. Avoid concomitant  CYP3A4 moderate or strong 
inhibitors/inducers, and sensitive substrates with a narrow  therapeutic index. AZD1775 is also a 
weak inhibitor of CYP2C19. Caution should  be exercised with concomitant administration of 
sensitive substrates or substrates with  a narrow therapeutic  index.  
 
In vitro transporter studies have s hown that AZD1775 was an inhibitor  of OATP1B1, OATP1B3, 
MATE1, MATE2K, P -glycoprotein (P -gp) and breast  cancer  resistance protein (BCRP), and a 
substrate for P -gp and BCRP. The PK parameters  of AZD1775 could be altered if AZD1775 is 
co-administered with  P- gp and BCRP inhibitors/inducers, and there is potential for drug -drug 
interactions  when  co-administered with OATP1B1, OATP1B3, MATE1, MATE2K, P -gp and  
BCRP substrates. This finding is particularly relevant for drugs administered orally  where 
exposure is n ormally limited by [CONTACT_69811] -mediated efflux, in particular some  statins. Modelling has 
predicted a substantial increase in the exposure of atorvastatin when  co- administered with 
AZD1775 and the use of atorvastatin is therefore  prohibited.  
 
Contraindications: Treatment with AZD1775 is contraindicated in  subjects with hypersensitivity 
to any component of the drug. Developmental and  reproductive toxicity studies of AZD1775 
have not been performed. AZD1775  is not to be given to women who are pre gnant or breast  
feeding.  
 
Availability AZD1775 is an investigational agent supplied to investigators  by [CONTACT_33997] (DCTD), NCI. AZD1775 is provided to the NCI under a 
Collaborative Agreement between the  Pharmaceutical  Collaborator and DCTD,  NCI.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
70 
 8.2   Agent Ordering and Agent Accountability  
 
NCI-supplied agents may be requested by [CONTACT_6768] (or their authorized 
designee) at each participating institution.  The CTEP -assigned protocol number must b e used 
for ordering all CTEP -supplied investigational agents.  The eligible participating investigators at 
each participating institution must be registered with CTEP, DCTD through an annual 
submission of FDA Form 1572 (Statement of Investigator), NCI Bios ketch, Agent Shipment 
Form, and Financial Disclosure Form (FDF).  If there are several participating investigators at 
one institution, CTEP -supplied investigational agents for the study should be ordered under the 
name [CONTACT_798222] r at that institution.  
 
In general, sites may order initial agent supplies when a subject is being screened for enrollment 
onto the study.  
 
Active CTEP -registered investigators and investigator -designated shippi[INVESTIGATOR_798171] t agent requests through the PMB Online Agent Order Processing 
(OAOP) application.  Access to OAOP re quires the establishment of a CTEP Identity and Access 
Management (IAM) account and the maintenance of an “active” account status and a “current” 
password.   For questions about drug orders, transfers, returns, or accountability, call or email 
PMB any time.  Refer to the PMB’s website for specific policies and guidelines related to agent 
management.   
 
Agent Inventory Records – The investigator, or a responsi ble party designated by [CONTACT_1275], must maintain a careful record of the receipt, dispensing and final disposition of all 
agents received from the PMB using the appropriate NCI Investigational Agent (Drug) 
Accountability Record (DARF) available on t he CTEP forms page.  Store and maintain separate 
NCI Investigational Agent Accountability Records for each agent, strength, formulation and 
ordering investigator on this protocol.  
 
8.3   Investigator Brochure Availability  
The current versions of the IB for the agent will be accessible to site investigators and research 
staff through the PMB Online Agent Order Processing (OAOP) application.  Access to OAOP 
requires the establishment of a CTEP Identity and Access Management ( IAM) account and the 
maintenance of an “active” account status , a “current” password , and active person registration 
status .  Questions about IB access may be directed to the PMB IB coordinator via email.  
 
8.4   Useful Links and Contacts  
Useful Links and Contacts:  
CTEP Forms, Templates, Documents:   http://ctep.cancer.gov/forms/  
NCI CTEP Investigator Registration:    [EMAIL_088]  
PMB policies and guidelines: http://ctep.cancer.gov/branches/pmb/agent_management.htm   
PMB Online Agent Order Processing (OAOP) application: 
https://ctepcore.nci.nih.gov/OAOP / CTEP Identity and Access Management (IAM) account: 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
71 
 https://ctepcore.nci.nih.gov/iam/index.jsp  
CTEP IAM account help:   [EMAIL_15198] v  
PMB email:   [EMAIL_087]  
IB Coordinator:  [EMAIL_413]  
PMB phone and hours of service:  (240) 276 -6575 Monday through Friday be tween 8:30 am 
and 4:30 pm (ET)  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
72 
 9. BIOMARKER, CORRELATIVES AND SPECIAL STUDIES  
 
9.1   Collection of Specimens  
 
Table 15: Summary of Specimen Requirements  
 
Time Point  Specimen and Quantity  Send Specimens to:  
Baseline  
 • 2 tissue cores snap -frozen  PADIS Laboratory, NCI -
Frederick  
 • Archival FFPE tumor block or 10 5 -
micron unstained slides  
• 1-2 cores snap -frozen  
• 10 mL blood in purple top EDTA tube  
• 10 mL blood in green top (sodium 
heparin) tube  Keyomarsi Laboratory  
 
 o   
 o   
C1D8  
 o 10 mL blood in purple top EDTA tube  
o 10 ml  blood in green top (sodium 
heparin) tube  Keyomarsi Laboratory  
C1D10 – 4h post dose (+/ - 1 h) 
 o 2 tissue cores, snap frozen  PADIS Laboratory, NCI 
Frederick  
 o 1-2 tissue cores, snap forzen  Keyomarsi Laboratory  
C2D1  
 o 10 mL blood in purple top EDTA tube  
o 10 ml  blood in green top (sodium 
heparin) tube  Keyomarsi Laboratory  
C2D8  
 o 10 mL blood in purple top EDTA tube  
o 10 ml blood in green top (sodium heparin) 
tube Keyomarsi Laboratory  
Progression/Relapse  
 o 2 tissue cores, snap frozen  
o 10 mL blood in purple top EDTA tube  
o 10 ml blood in green top (sodium heparin) 
tube Keyomarsi Laboratory  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
73 
  
Due to the nature of the correlative analysis, fresh biopsies are necessary . A minimum of four 
core biopsy samples (18 gauge cores) should be attained.  Please  see Appendix D for detailed 
instructions and  request sam ple shipment kits directly from NCI. Biopsy costs are covered for all 
ETCTN sites.  
 
Note that if any site is unable to send flash frozen biopsy tissue, please contact [INVESTIGATOR_124]. Siqing Fu 
and [CONTACT_798229] for a case by [CONTACT_798208].  
Time Point  Specimen and Quantity  Send Specimens  to: 
Baseline  
 • 2 tissue cores snap -frozen   PADIS Laboratory, NCI -Frederick  
 • Archival FFPE tumor block or 10 5 -micron 
unstained slides  
• 1-2 cores snap -frozen  
• 10 mL blood in purple top EDTA tube  
• 10 mL blood in green top (sodium heparin) 
tube Keyomarsi Laboratory  
04h post dose 5  
 • 2 tissue cores, snap -frozen  PADIS Laboratory, NCI -Frederick   
 • 1-2 tissue cores, snap -frozen   Keyomarsi Laboratory  
C1D8  
 • 10 mL blood in purple top EDTA  tube 
• 10 ml  blood in green top (sodium heparin) 
tube Keyomarsi Laboratory  
C1D10 – 4h po st dose (+/ - 1 h) 
 • 2 tissue cores, snap frozen  PADIS Laboratory, NCI Frederick  
 • 1-2 tissue cores, snap forzen  Keyomarsi Laboratory  
C2D1  
 • 10 mL blood in purple top EDTA  tube 
• 10 ml  blood in green top (sodium heparin) 
tube Keyomarsi Laboratory  
C2D8  
 • 10 mL blood in purple top EDTA tube  
• 10 ml blood in green top (sodium heparin) 
tube Keyomarsi Laboratory  
Progression/Relapse  
 • 2 tissue cores, snap frozen  
• 10 mL blood in purple top EDTA  tube 
• 10 ml blood in green top (sodium heparin) 
tube Keyomarsi Laboratory  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100887] 10ml of whole blood in lavender/purple top Vacutainer 
tube (EDTA) and 10ml in green top Vacutainer tube (sodium heparin). After sample 
collection, gently invert tubes 5 -10 times to mix the blood with the t ube additive. All tubes 
should be labelled with the patient’s study ID. Ship whole blood to the address below for 
[CONTACT_798230]’s laboratory on the day the biospecimen is collected. If the whole blood 
absolutely cannot be shipped the day it is collected, t he tube(s) should be refrigerated (4°C) 
and shipped within [ADDRESS_1100888]. Keyomarsi’s labs will isolate DNA for NGS sequencing and PBMCs and plasma. 
PBMCs and plasma will be isolated using Ficoll density gradient and cryopreserved in 
liquid nitrogen in 10%  DMSO and 90% human AB serum at 10 × 106 cells/vial. Plasma will 
be stored at -70°C (0.5 -1 mL/vial) until later analysis.  
 
 
2.16 9.2   Shippi[INVESTIGATOR_52137]  
1. Two cores  per time point  should be sent to  the Pharmacodynamics Assay Development & 
Implementation Section (PADIS) laboratory at NCI, where they will be embedded.  Monthly 
batch shipment is allowed.  
 
The shippi[INVESTIGATOR_798172] 8.3 and 8.4  
 
Attention: Dan Danner  
NCI-F/FNLCR  
[ADDRESS_1100889], Building 1073  
Fort Detrick  
Frederick, MD [ZIP_CODE]  
Phone: [ADDRESS_1100890]. Siqing Fu by [CONTACT_798209] a 
shipment. A separate email with FedEx shippi[INVESTIGATOR_798173] l be sent to the research nurse 
for shipment.  
 
Note that FedEx  packages should not be shipped any later than Thursday mornings for overnight 
to the facility, and should not be shipped to arrive on Federal holidays because the receiving 
docks are closed on weekends and holidays.  
 
 
Robert Kinders: [EMAIL_15199]   
TEL: [PHONE_16654]  
Sr. Principal Scien tist 
Head, Pharmacodynamics Section  
Clinical Pharmacodynamics Program  Rachel Andrews:   [EMAIL_15200]  
TEL: 240 -344-5697.  
 
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
75 
 Applied/Developmental Research Directorate  
Frederick National Laboratory/Leidos  
 
2. Two additional  cores, along with pharmacodynamics  blood samples should be sent to [CONTACT_798231] ’s laboratory at MD Anderson Cancer Center. Please contact [INVESTIGATOR_124]. Siqing 
Fu should you have any questions.  
 
Khandan Keyomarsi  
Zayed Building for Personalize (Z6.3012)  
[ADDRESS_1100891].  
Unit 0066  
Houston, TX [ZIP_CODE]  
[EMAIL_15201]  
 
 
10.  STUDY CALENDAR  
 
Baseline evaluations are to be conducted within [ADDRESS_1100892] be done <4 weeks prior to the start of therapy.  In the event that the patient’s 
condi tion is deteriorating, laboratory evaluations should be repeated within 48 hours prior to 
initiation of the next cycle of therapy  (Table 15). 
 
Table 16:  Phase I I Study of AZD1775 in CCNE1 Amplified Patients   
 
 
  
Assessment  Tool  
Screeninga  
Baselineb Cycle  1 p Cycle 2, 3, 4,  … p 
End of Studyc Week  Week  
1 2 3 1 2 3 
AZD1775  d   X X  X X   
Medical  history  X        X 
Physical exam    X X   X   X 
ECOG performance status  e  X X   X   X 
CBC with  differential   X X X X X   X 
Serum chemistries  (electrolytes, 
hepatic  and renal function  tests)   X X X X X   X 
Pregnancy test  f X  X   X   X 
Triplicate ECG g X  X   X    
ECHO/MUGAh X         
Urinalysis  i X        X 
Tumor markers, if available  j X        X 
Radiological evaluations  (CT, MRI 
or PET as appropriate)  k X        X 
Pharmacodynamics (blood)  l   X X  X X  X 
Tumor specimens  m  X  X      
Adverse event assessment  n X 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
76 
 Concurrent  medications  X 
DLT assessment  o   X  
a) Screening visit to occur within 4 weeks prior to initiation of  therapy  
b) Baseline visit to occur within 7 days prior to initiation of  therapy  
c) End of study visit to occur within [ADDRESS_1100893] dose of study agents, if  feasible  
d) This agent is administered orally daily from D1 to D5 (Week 1) and D8-D12 (Week 2), there will not be 
agent administration for Week 3 of each cycle. One cycle is 21 days in  length  
e) To be obtained at the screening, on Day 1 of each  cycle of  therapy  and at EOT  
f) To be tested in women of child -bearing potential prior to the enr ollment, on Day 1 of each cycle of 
therapy and at EOT  
g) Triplicate [ADDRESS_1100894] be <450 msec for male patients and <470 
msec for female patients. Triplicate 12 -lead ECGs will be conducted approximately 2 -5 minutes apart prior to 
dosing  
h) To be obtained at screening and then as clinically indicated  
i) To be obtained at screening then periodically as indicated  clinically  
j) To be tested at screening and with each restaging if abnormal at baseline, or more frequently as  
appropriate  
k) To be performed at screening, once approximately at 9 weeks, another at 18 weeks an d also at 27 
weeks +/ - 7 days or sooner if clinically indicated, and then every 12 weeks or sooner if clinically  
indicated  
l) To collect pharmacodynamics blood samples ( 20 mL each collection: plasma and peripheral blood 
monocytes):  mandatory on cycle 1 day 1 pre-dose  and optional on cycle 1 day 8, cycle 2 day 1, cycle 2 
day 8, and at the end of study , if feasible . Optional blood (about 10 mL) will be collected with option al 
tumor biopsy on C1D10 or at  relapse.  
m) Mandatory  tumor biopsy pre -study and archived tumor tissues (ten 5 µm-thick slides) , if available . 
Additional mandatory tumor biopsy on C1D10 at 4 hours  (± 2 hours)  post dose.  Optional biopsies will be 
collected at relapse if a patient has achieved a partial remission or complete remission .  
n) Adverse events to be assessed at all study visits and/or over the phone as clinically  indicated  
o) DLT assessment to occur with [ADDRESS_1100895]  dose  
p) Assessments should occur within +/ - [ADDRESS_1100896] – Solid Tumors  
For the purposes of this study, patients should be re -evaluated for response ever y 9 weeks.  In 
addition to a baseline scan, confirmatory scans should also be obtained 4 (not less than 4) weeks 
following initial documentation of objective response.  
 
Response and progression will be evaluated in this study using the new international cr iteria 
proposed by [CONTACT_459] (R ECIST) guideline 
(version 1.1) [51].  Changes  in the largest diameter (unidimensional measurement) of the tumor 
lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST 
criteria.  
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100897] their response classified 
accor ding to the definitions stated below.  (Note:  Patients who exhibit objective disease 
progression prior to the end of cycle 1 will also be considered evaluable.)  
 
11.[ADDRESS_1100898] one dimension (longest diameter to be recorded) as ≥20 mm (≥2 c m) by [CONTACT_13190] x -ray or as 
≥10 mm  (≥1 c m) with CT scan, MRI, or calipers by [CONTACT_461].  All tumor measurements 
must be recorded in millimeters  (or decimal fra ctions of centimeters).  
 
Note:  Tumor lesions that are situated in a previously irradiated area might or might not be 
considered measurable.   
 
Malignant lymph nodes.   To be considered pathologically enlarged and measurable, a lymph 
node must be ≥15 mm  (≥1.5 cm) in short axis when assessed by [CONTACT_3610] (CT scan slice 
thickness recommended to be no greater than 5 mm  [0.5 cm] ).  At baseline and in follow -up, 
only the short axis will be measured and followed.  
 
Non-measurable disease .  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm  [<1 cm]  or pathological lymph nodes with ≥ 10 to <15 mm  [≥1 to <1 .5 cm] 
short axis), are considered non -measurable disease.  Bone lesions, leptomeningeal disease, 
ascites, pleural/pericardi al effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, 
and abdominal masses (not followed by [CONTACT_462]), are considered as non -measurable.  
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not  
be considered as malignant lesions (neither measurable nor non -measurable) since they are, by 
[CONTACT_108], simple cysts.  
 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, 
if they meet the definition of measur ability described above. However, if non -cystic lesions are 
present in the same patient, these are preferred for selection as target lesions.  
 
Target lesions.   All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representa tive of all involved organs, should be identified as target lesions  and recorded 
and measured at baseline.  Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in a ddition should be 
those that lend themselves to reproducible repeated measurements.  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in which 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100899] lesion which can be measur ed reproducibly should be selected.  A 
sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, t hen only the short axis is added into the sum.  The baseline sum diameters 
will be used as reference to further characterize any objective tumor regression in the measurable 
dimension of the disease.  
 
Non-target lesions .  All other lesions (or sites of dis ease) including any measurable lesions over 
and above the 5 target lesions should be identified as non-target lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the presence, absence, 
or in rare cases uneq uivocal progression of each should be noted throughout follow -up.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
79 
 11.3   Methods for Evaluation of Measurable Disease  
 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment.  
 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and  during follow -up. Imaging -based evaluation is 
preferred to evaluation by [CONTACT_460](s) being followed cannot be 
imaged but are assessable by [CONTACT_461].  
 
Clinical lesions   Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥10 mm  (≥1 cm)  diameter as assessed using 
calipers ( e.g., skin nodules).  In the case of skin lesions, documentation by [CONTACT_6775], 
including a ruler to estimate the size of the lesion, is recommended.  
 
Chest x -ray  Lesions on chest x -ray are acceptable as measurable lesions when they are clearly 
define d and surrounded by [CONTACT_6776].  However, CT is preferable.  
 
Conventional CT and MRI   This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm  (0.5 cm)  or less.  If CT scans have slice 
thickn ess greater than 5 mm  (0.5 cm) , the minimum size for a measurable lesion should be twice 
the slice thickness.  MRI is also acceptable in certain situations ( e.g. for body scans).   
 
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly 
impact image quality, lesion conspi[INVESTIGATOR_3934], and measurement.  Furthermore, t he availability of 
MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications of the 
scanning sequences used should be optimized for the evaluation of the type and site of disease.  
Furthermore, as with CT, the modality use d at follow -up should be the same as was used at 
baseline and the lesions should be measured/assessed on the same pulse sequence.  It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all 
scanners, body pa rts, and diseases.  Ideally, the same type of scanner should be used and the 
image acquisition protocol should be followed as closely as possible to prior scans.  Body  scans 
should be performed with breath -hold scanning techniques, if possible.  
 
PET-CT  At present, the low dose or attenuation correction CT portion of a combined PET -CT is 
not always of optimal diagnostic CT quality for use with RECIST measurements.  However, if 
the site can document that the CT performed as part of a PET -CT is of identical d iagnostic 
quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET -CT can be 
used for RECIST measurements and can be used interchangeably with conventional CT in 
accurately measuring cancer lesions over time.  Note, however, t hat the PET portion of the CT 
introduces additional data which may bias an investigator if it is not routinely or serially 
performed.   
 
Ultrasound   Ultrasound is not useful in assessment of lesion size and should not be used as a 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100900] in selected instances.  
 
Endoscopy, Laparoscopy   The utilization  of these techniques for objective tumor evaluation is 
not advised.  However, such techniques may be useful to confirm complete pathological 
response when biopsies are obtained or to determine relapse in trials where recurrence following 
complete response (CR) or surgical resection is an endpoint.  
 
Tumor markers   Tumor markers alone cannot be used to assess response.  If markers are initially 
above the upper normal limit, they must normalize for a patient to be considered in complete 
clinical response.  Spe cific guidelines for both CA -125 response (in recurrent ovarian cancer) 
and PSA response (in recurrent prostate cancer) have been published [ JNCI  96:487 -488, 2004; J 
Clin Oncol  17, 3461 -3467, 1999; J Clin Oncol  26:1148 -1159, 2008].  In addition, the 
Gyneco logic Cancer Intergroup has developed CA -[ADDRESS_1100901] -line trials in ovarian cancer [ JNCI  
92:1534 -1535, 2000].  
 
Cytology, Histology   These techniques can be used to dif ferentiate between partial responses 
(PR) and complete responses (CR) in rare cases ( e.g., residual lesions in tumor types, such as 
germ cell tumors, where known residual benign tumors can remain).  
 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease (an effusion may be a side effect of 
the treatment) and progres sive disease.  
 
FDG -PET  While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesio ns on the basis of 
FDG -PET imaging can be identified according to the following algorithm:  
− Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD based 
on a new lesion.  
− No FDG -PET at baseline and a positive FDG -PET at follow -up:  If the positive FDG -PET at 
follow -up corresponds to a new site of disease confirmed by [CONTACT_4654], this is PD.  If the positive 
FDG -PET at follow -up is not confirmed as a new site of disease on CT, addit ional follow -up 
CT  scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD will be the date of the initial abnormal FDG -PET scan).  If the positive FDG -PET 
at follow -up corresponds to a pre -existing site o f disease on CT that is not progressing on the 
basis of the anatomic images, this is not PD.  
− FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibros is or scarring.  
The use of FDG -PET in this circumstance should be prospectively described in the protocol 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100902] be 
acknowledged that both approaches may lead to false pos itive CR due to limitations of FDG -
PET and biopsy resolution/sensitivity.  
 
Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
82 
 11.4   Respons e Criteria  
 
Evaluation of Target Lesions  
 
Complete Response (CR) :  Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non -target) must have reduction in short axis to <10 mm  (<1 cm) . 
 
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum diameters.  
 
Progressive Disease (PD) :  At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (th is includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must also demonstrate an 
absolute increase of at least 5 mm  (0.5 cm) .  (Note:  the appearance of one or more new lesions is 
also considere d progressions).  
 
Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.  
 
 
Evaluation of Non -Target Lesions  
 
Complete Response (CR) :  Disappearance of all non -target lesions and normalization of tumor 
marker level.  All lymph nodes must be non -pathological in size (<10 mm  [<1 cm]  short axis).  
 
Note:  If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinical response.  
 
Non-CR/Non -PD:  Persistence of one or more non -target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.  
 
Progressive Disease (PD) :  Appearance of one or more new lesions and/or  unequivocal 
progression  of existing non -target lesions.  Unequivocal progression  should not normally trump 
target lesion status.  It must be representative of overall disease status change, not a single lesion 
increase.  
 
Although a clear progression of “n on-target” lesions only is exceptional, the opi[INVESTIGATOR_12999], and the progression status should be 
confirmed at a later time by [CONTACT_463] (or Principal Investigator).  
 
 
Evaluation of Best Overall  Response  
 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started).  The patie nt's best response assignment will 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
83 
 depend on the achievement of both measurement and confirmation criteria  (Tables 15 and 16) . 
 
  Table 17:  For Patients with Measurable Disease ( i.e., Target Disease)  
Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR ≥4 wks. Confirmation**  
CR Non-CR/Non -
PD No PR 
≥4 wks. Confirmation**  CR Not evaluated  No PR 
PR Non-CR/Non -
PD/not 
evaluated  No PR 
SD Non-CR/Non -
PD/not 
evaluated  No SD Documented at least once ≥4 
wks. from baseline**  
PD Any Yes or No  PD 
no prior SD, PR or CR  Any PD***  Yes or No  PD 
Any Any Yes PD 
 See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
**    Only for non-randomized trials with response as primary endpoint.  
***  In exceptional circumstances, unequivocal progression in non -target lesions may be  
accepted as disease progression.  
 
Note :  Patients with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration.”   Every effort should be made to document the objective 
progression even after discontinuation of treatm ent. 
 
  Table 17:  For Patients with Non -Measurable Disease ( i.e., Non -Target Disease)  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
 ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials so to assign this 
category when no lesions can be measured is not advised  
 
 
Duration of Response  
 
Duration of overall response :  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
84 
 recurrent or progressive disease is objectivel y documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started).  
 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive  disease is objectively documented.   
 
Duration of stable disease :  Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the 
treatment started, including the baseline measurements.  
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
85 
 12.   STUDY OVERSIGHT AND  DATA REPORTING / REGULATORY 
REQUIREMENTS  
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 
(Adverse Events: List and Reporting Requirements).  
 
12.[ADDRESS_1100903] and progress of the clinical trial, including 
the ongoing review of accrual, patient -specific clinical and laboratory data , and ro utine  and 
serious  adverse events ; reporting of expedited adverse events;  and accumulation of reported 
adverse events from other trials testing the same drug(s).  The Protocol Principal Investigator [INVESTIGATOR_798174] t he CTMS web-based reporting portal.   
 
During the Phase [ADDRESS_1100904], at a minimum, quarterly 
conference calls with the Study Investigators and the CTEP Medical Officer(s) to review accrual, 
progress, and pharmacovigilance.  Decisions to proceed to the second stage of a Phase 2 trial will 
require sign -off by [CONTACT_124456] [INVESTIGATOR_485177].  
   
All Study Investigators at participating sites who register/enroll patients on a given protocol are 
responsible for timely submission of data via Medidata Rave and timely reporting of adverse 
events for that particular study.  This includes timely review of data collected on the electronic 
CRFs submitted via Medidata Rave.  
 
All studies  are also reviewed in accordance with the enrolling institution’s data safety monitoring 
plan.   
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100905] is granted through the iMedidat a application to all persons with the appropriate 
roles assigned in the Regulatory Support System (RSS).  To access Rave via iMedidata, the site 
user must have an active CTEP IAM account (check at < https:// ctepcore.nci.nih.gov/iam   >) and 
the appropriate Rave role (Rave CRA, Read -Only, CRA , Lab Admin, SLA , or Site Investigator) 
on either the LPO or participating organization roster at the enrolling site. To th e hold Rave CRA 
role or CRA Lab Admin role, the user must hold a minimum of an AP registration type.  To hold 
the Rave Site Investigator role, the individual must be registered as an NPI[INVESTIGATOR_6735].  
Associates can hold read -only roles in Rave.  Upon initial site registration approval for the study 
in RSS, all persons with Rave roles assigned on the appropriate roster will be sent a study 
invitation e -mail from iMedidata.  To accept the invitation, site users must log into the Select 
Login ( https://login.imedidata.com/selectlogin ) using their CTEP -IAM user name [CONTACT_2383], 
and click on the “accept” link in the upper right -corner of the iMedidata page.  Please note, site 
users will not be able to access t he study in Rave until all required Medidata and study specific 
trainings are completed.  Trainings will be in the form of electronic learnings (eLearnings),  and can 
be accessed by [CONTACT_261352] .   
 
Users that have not previously activated their iMedidata/Rave account at the time of initial site 
registration approval for the study in RSS  will also receive a separate invitation from iMedidata 
to activate their account. Account activation instructions are located on the CTSU website, Rave 
tab under the Rave resource materials (Medidata Account Activation and Study Invitation 
Acceptance).  Ad ditional information on iMedidata/Rave is available on the CTSU members’ 
website under the Rave tab or by [CONTACT_6821] 1 -[PHONE_103] or by e -
mail at [EMAIL_013] . 
 
Method  
 
This st udy will be monitored by [CONTACT_25540] (CTMS).  Data will be 
submitted to CTMS at least once every two weeks via Medidata Rave (or other modality if 
approved by [CONTACT_472]).  Information on CTMS reporting is available at:  
http://www.theradex.com/clinicalTechnologies/?National -Cancer -Institute -NCI-11.  On -site 
audits will be conducted on an [ADDRESS_1100906] the Theradex Help Desk at (609) 79 9-7580 or by [CONTACT_25541] 
[EMAIL_411]  for additional support with Rave and completion of CRFs.  
 
 
Responsibility for Data Submission  
 
For ETCTN trials, i t is the responsibility of the PI(s) at the sit e to ensure that all investigators at 
the ETCTN Sites understand the procedures for data submission for each ETCTN protocol and 
that protocol specified data are submitted accurately and in a timely manner to the CTMS via the 
electronic data capture system,  Medidata Rave.   
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100907] for the CRA at the ETCTN to resolve.   Monthly web -
based reports are posted for review by [CONTACT_25542], CTEP.  Onsite audits will 
be conducted by [CONTACT_182663], GCP, and NCI 
policies and procedures with the overarching goal of ensurin g the integrity of data generated 
from NCI -sponsored clinical trials , as described in the ETCTN Program Guidelines, which may 
be found on the CTEP 
(http:/ /ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htm )  and 
CTSU websites.  
 
An End of Study CRF  is to be completed by [CONTACT_978] , and is  to include a summary of study 
endpoints not otherwise captured in the database, such as (for phase I trials) the recommended 
phase 2 dose (RP2D), and a description of any dose -limiting toxicities  (DLTs) .  CTMS will 
utilize a core set of eCRFs that are Cancer Data Sta ndards Registry and Repository  (caDSR) 
compliant  (http://cbiit.nci.nih.gov/ncip/biomedical -informatics -resources/interoperabil ity-and-
semantics/metadata -and-models ).  Customized eCRFs will be included when appropriate to meet 
unique study requirements.  The PI [INVESTIGATOR_278583] , working closely with 
CTMS to ensure prospectively that all required items are appropri ately captured in the eCRFs 
prior to study activation.  CTMS will prepare the eCRFs with built -in edit checks to the extent 
possible to promote data integrity.  
 
CDUS data submissions for ETCTN trials activated after 03/01/ 2014, will be carried out by [CONTACT_798210], Theradex.  CDUS submissions are performed by [CONTACT_278277] a monthly 
basis.  The trial’s lead institution is responsible for timely submission to CTMS via R ave. 
 
Further information on data submission procedures can be found in the ETCTN Prog ram 
Guidelines 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htm ). 
 
 
12.3   CTEP Multicenter Guidelines  
 
N/A 
 
 
12.4   Collaborative Agreements Language  
The agent(s) supplied by [CONTACT_472], DCTD, NCI used in this protocol is/are provided to the NCI 
under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
88 
 Company(ies) (hereinafter referred to as “Collaborator( s)”) and the NCI Division of Cancer 
Treatment and Diagnosis.  Therefore, the following obligations/guidelines, in addition to the 
provisions in the “Intellectual Property Option to Collaborator ”  
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ) contained within the 
terms of award, apply to the use of the Agent(s) in this study:  
 
1. Agent(s) may not be used for any purpose outside the scope of t his protocol, nor can Agent(s) 
be transferred or licensed to any party not partic ipating in the clinical study.  Collaborator(s) data 
for Agent(s) are confidential and proprietary to Collaborator(s) and shall be maintained as such 
by [CONTACT_473].  The protocol documents for studies utilizing Agents contain confidential 
information and should not be shared or distributed without the pe rmission of the NCI.  If a copy 
of this protocol is requested by a patient or patient’s family member participating on the study, 
the individual should sign a confidentiality agreement.  A suitable model agreement can be 
downloaded from: http://ctep.cancer.gov . 
 
2. For a clinical protocol where there is an investigational Agent used i n combination with 
(an)other Agent(s), each the subject of different Collaborative Agreements, the access to and use 
of data by [CONTACT_474] (data pertaining to such combination use shall 
hereinafter be referred to as "Multi -Party Data ”): 
 
a. NCI will provide all Collaborators with prior written notice regarding the existence and nature 
of any agreements governing their collaboration with NCI, the design of the proposed 
combination protocol, and the existence of any obligations that  would tend to restrict NCI's 
participation in the proposed combination protocol.  
 
b. Each Collaborator shall agree to permit use of the Multi -Party Data from the clinical trial by 
[CONTACT_798211] C ollaborator to develop, 
obtain regulatory approval or commercialize its own Agent.  
 
c. Any Collaborator having the right to use the Multi -Party Data from these trials must agree in 
writing prior to the commencement of the trials that it will use the Multi -Party Data solely for 
development, regulatory approval, and commercialization of its own Agent.  
 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement 
will be made available to Collaborator(s), the NCI, and the FDA , as appropriate and unless 
additional disclosure is required by [CONTACT_110708]  (http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ).  
Additionally, all Clinical Data and Results and Raw Data will be collected , used and disclose d 
consistent with all applicable federal statutes and regulations for the protection of human 
subjects, including, if applicable, the Standards for Privacy of Individually Identifiable Health 
Information  set forth in [ADDRESS_1100908] be sent to the 
NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group 
studies, or PI [INVESTIGATOR_349]) of Collaborator's wish to contact [CONTACT_476].  
 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
89 
 5. Any dat a provided to Collaborator(s) for Phase [ADDRESS_1100909] be in accordance with the 
guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a DMC 
for this clinical trial.  
 
6. Any manuscripts reporting the results of this clinic al trial must be provided to CTEP by [CONTACT_25545] [INVESTIGATOR_350] -Cooperative 
Group studies for immediate delivery to Collaborator(s) for advisory review and comment prior 
to submission for publica tion.  Collaborator(s) will have [ADDRESS_1100910] that publication be delayed for up to an 
additional 30 days in order to ensure that Collaborator’s confidential and proprietary data , in 
addition to Collaborator(s)’s intellectual p roperty rights, are protected.  Copi[INVESTIGATOR_798175](s) for courtesy review as soon as possible 
and preferably at least three (3) days prior to submissi on, but in any case, prior to presentation at 
the meeting or publication in the proceedings.  Press releases and other media presentations must 
also be forw arded to CTEP prior to release.  Copi[INVESTIGATOR_352], abstract and/or press 
release/ media pres entation should be sent to:  
 
Email:   [EMAIL_001]  
 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No publication, 
manuscript or other form of public disclosure shall contain any of Collaborator ’s confidential/ 
proprietary information.  
 
12.5   Genomic Data Sharing Plan  
N/A 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
90 
 12.6   Safety Monitoring  
 
The site investigators will meet by [CONTACT_302847] a weekly frequency for approximately 30 
minutes. The site investigator(s) and research staff involved with the conduct of the protocol are 
required to attend. During the weekly teleconference, the inves tigators will discuss:  
•  Safety of protocol p articipants (AEs and reporting)   
•  Validity and integrity of the data (data completeness on case report forms and complete 
source documentation)  
•  Enrollment rate relative to expectation of target accrual ( eligible and ineligible participants)  
•  Retention of participants, adherence to the protocol, and protocol violations  
•  Protocol amendments  
 
 
12.7   Data Safety Monitoring Plan  
 
The MD Anderson Cancer Center  Data and Safety Monitoring Committee (DSMC) wil l provide 
the primary oversight of data and safety monitoring. The MD Anderson  DSMC will review and 
monitor compliance, toxicity and deviations from this study. The committee is composed of 
clinical specialists with experience in oncology. Information that  raises any questions about 
participant safety will be addressed with the Principal Investigator.  
 
The DSMC will review this protocol at a minimum of once every six months. Information to be 
provided to the committee includes: a study narrative by [CONTACT_978],  a summary DSMC report 
produced by [CONTACT_798212]/Theradex which includes participant accrual, response, trial status history, 
SAEs, Adverse Events, Deviations and survival); audit results, and monitoring reports as 
applicable. Other information (e.g. scans, laborat ory values) will be provided upon request.  
 
The MD Anderson Can cer Center Office of Investigational New Drug/Device (the MD Anderson 
IND Office) will audit the trial at least annually or as determined by [CONTACT_798213]. 
The overall principal investi gator, study coordinator and/or data manager may request access to 
all source documents and other study documentation for on -site or remote monitoring, audit or 
inspection.  
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
91 
 13  STATISTICAL CONSIDERATIONS  
 
13.1  Study Design/Endpoints  
 
The primary endpoint is objective response rate (ORR), defined as a CR or PR within [ADDRESS_1100911] a null benchmark val ue of 5%. A maximum of 
[ADDRESS_1100912] a response, it will then be concluded that the 
agent is promising and worthy of further testing. Allowing for 10% ineligibility or dropout rate, 
we will accrue 32 patients to o btain 29 evaluable patients.  
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
92 
 13.2  Sample Size/Accrual Rate  
 
The ORR rate will be compared against a null benchmark value of 5%. If the observed objective 
response rate is ≥ 4/29 (14%), it will then be concluded that the agent is promising and worthy of 
further testing. Allowing for 10% ineligibility or dropout rate,  a total of  32 patients will need to 
be accrued in order to obtain 29 evaluable patients (Table 17).  If a response has been observed in 
a particula r tumor type, then the study may be expanded to  include a total of [ADDRESS_1100913] one of these 10 patients has a response, we will continue to a second stage o f 19 
patients. The proposed design has the following operating characteristics: power is 80% to 
conclude an agent is promising if the true ORR is 0.2; type 1 error rate (one -sided) is 6% (this is 
the probability to conclude that a given agent is promising if the true ORR is 0.05). If the true 
ORR is 0.05, there is a 49% chance of stoppi[INVESTIGATOR_798176].  
 
Table 1 8:  PLANNED ENROLLMENT REPORT  
Racial Categories  Ethnic Categories  
Total  
Not Hispanic or Latino  Hispanic or Latino  
 Female  Male  Female  Male   
American Indian/ 
Alaska Native  1 1 0 1 3 
Asian  1 1 1 0 3 
Native Hawaiian or 
Other Pacific Islander  1 0 1 1 3 
Black or African 
American  1 1 1 1 4 
White  4 3 3 3 13 
More Than One Race  2 1 1 2 6 
Total      32 
PHS 398 / PHS 2590 (Rev. 08/12 Approved Through 8/31/2015)   OMB No. 0925 -0001/[ADDRESS_1100914] be assessed for response to treatment to be assigned one of the following 
categories, even if there are major protocol treatment deviations or if they are ineligible.  
1) Complete response                                              
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
93 
 2) Partial response  
3) Stable disease                                                      
4) Progressive disease  
5) Early death from malignant disease                     
6) Early death from toxicity  
7) Early death because of other cause                      
8) Unknown (not assessable, insufficient data)  
 
Categorization of response will be based on RECIST 1.1. All of the patients who meet the 
eligibility criteria (with the possible exception of those who received no study medication) will 
be included in the main analysis of the response rate. Patients in response categories 4 -8 as above 
should be considered as failing to respond to therapy (disease progression). A patient will be 
determined as having a response if he/she has CR or PR; a pat ient will be determined as a non -
response if there is no evidence of response by [ADDRESS_1100915] 
treatment schedule or drug administration does not result in exclusion from the analysis of the 
response rate.  
 
The method of T hall, Simon, and Estey  [52] will be employed to perform interim safety 
monitoring. We will assume a Beta (.3, .7) prior distribution for the DLT rate, and target a 30% 
DLT rate and we will terminate enrollment into the trial if Pr{DLT   rate > 30%| data} > 0.9. That 
is, if at any time during the study we determine that there is more than a 90% chance that the 
DLT rate is more than 30% we will stop enrollment. We will monitor at 10 and 20 patients  with 
a possible maximum of 32 patients . Stoppi[INVESTIGATOR_798177] [# of patients with DLT/ # of patients evaluated] ≥5/10, 8/20 . 
The op erating characteristics of this rule in the trial are shown in Table 18.   
 
Table 19:  Operating Characteristics for Safety Monitoring Rule  
True DLT Rate  Probability of Early Termination (PET) Mean number of patients  
10% 0% 32.0 
20% 5% 31.0 
30% 28% 27.1 
40% 63% 20.7 
50% 89% 15.[ADDRESS_1100916]. PFS and OS will 
be estimated using the Kaplan -Meier method. In correlative mechanism studies, we will focus on 
the association between clinical responses and potential biomark ers and on comparison of 
biomarkers before and after treatment. Statistical inferences will be based on 2 -sided tests at a 
significance level of P<0.05. In [ADDRESS_1100917] 80% power for a paired t-test to 
NCI Protocol #: [ZIP_CODE]  
Version Date:  [ADDRESS_1100918] deviation mean difference, assuming a 2 -sided alpha 5% level. To compare 
biomarker levels between responders and non -responders, the study will have 80% power for a 
2-sampl e t-test to detect a 1.[ADDRESS_1100919] deviation mean difference, using a 2 -sided 5% alpha level 
if the response rate is 25% and N = 20. Non -parametric analogs of the t-tests will be used if the 
data violate the assumptions of the t-test. 
 
 
13.[ADDRESS_1100920]. 
Otherwise patients will be removed from the study for one of the following stop rules:  
 
•  Any unco ntrolled side effect affecting quality of life.  
•  Intercurrent illness that prevents further administration of treatment.  
•  At least 20% increase in tumor burden compared with nadir.  
•  Patient chooses to withdraw. Patients can stop participating at any time.  
•  The researcher may decide to take a patient off under several circumstances: discontinuing is 
in the participant's medical best interest, funding is stopped, agent supply is insufficient, patient's 
condition worsens, or new information becomes av ailable  
 
 
 
 
 
  
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
95 
 REFERENCES  
 
1. Indovina P, Giordano A. Targeting the checkpoint kinase WEE1: selective sensitization of 
cancer cells to DNA -damaging drugs. Cancer Biol Ther 2010; 9: 523 -525. 
2. De Witt Hamer PC, Mir SE, Noske D et al. WEE1 kinase targeting combined with DNA -
damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 2011; 17: 4200 -4207.  
3. Li C, Andrake M, Dunbrack R, Enders GH. A bifunctional regulatory element in human 
somatic Wee1 mediates cyclin A/Cdk2 bi nding and Crm1 -dependent nuclear export. Mol Cell 
Biol 2010; 30: 116 -130. 
4. Mizuarai S, Yamanaka K, Itadani H et al. Discovery of gene expression -based 
pharmacodynamic biomarker for a p53 context -specific anti -tumor drug Wee1 inhibitor. Mol 
Cancer 2009; 8 : 34. 
5. Sherr CJ. Cancer cell cycles. Science 1996; 274: [ADDRESS_1100921] sarcoma cells. Mol Cancer Ther 2012; 11: 174 -182. 
7. Bridges KA , Hirai H, Buser CA et al. MK -1775, a novel Wee1 kinase inhibitor, 
radiosensitizes p53 -defective human tumor cells. Clin Cancer Res 2011; 17: 5638 -5648.  
8. Hirai H, Arai T, Okada M et al. MK -1775, a small molecule Wee1 inhibitor, enhances anti -
tumor effica cy of various DNA -damaging agents, including 5 -fluorouracil. Cancer Biol Ther 
2010; 9: 514 -522. 
9. Hirai H, Iwasawa Y, Okada M et al. Small -molecule inhibition of Wee1 kinase by [CONTACT_90338] -1775 
selectively sensitizes p53 -deficient tumor cells to DNA -damaging agent s. Mol Cancer Ther 
2009; 8: 2992 -3000.  
10. Rajeshkumar NV, De Oliveira E, Ottenhof N et al. MK -1775, a potent Wee1 inhibitor, 
synergizes with gemcitabine to achieve tumor regressions, selectively in p53 -deficient pancreatic 
cancer xenografts. Clin Cancer R es 2011; 17: [ADDRESS_1100922] followed by [CONTACT_798214]. Mol Cancer Ther 2 015; 14: 608 -619. 
12. Osman AA, Tanaka N, Patel AA et al. Wee -1 kinase inhibition sensitizes high risk HPV+ 
HNSCC to apoptosis accompanied by [CONTACT_798215] -1 and XIAP antiapoptotic 
proteins. Clin Cancer Res 2015.  
13. Do K, Wilsker D, Ji J et al. Ph ase I Study of Single -Agent AZD1775 (MK -1775), a Wee1 
Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol 2015.  
14. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by [CONTACT_798216] G1 cyclin 
(Cln) function in yeast. Cell 1 991; 66: 1197 -1206.  
15. Koff A, Cross F, Fisher A et al. Human cyclin E, a new cyclin that interacts with two 
members of the CDC2 gene family. Cell 1991; 66: 1217 -1228.  
16. Koff A, Giordano A, Desai D et al. Formation and activation of a cyclin E-cdk2 complex 
during the G1 phase of the human cell cycle. Science 1992; 257: 1689 -1694.  
17. Coller HA, Grandori C, Tamayo P et al. Expression analysis with oligonucleotide 
microarrays reveals that MYC regulates genes involved in growth, cell cycle, signa ling, and 
adhesion. Proc Natl Acad Sci U S A 2000; 97: 3260 -3265.  
18. Zhang HS, Gavin M, Dahiya A et al. Exit from G1 and S phase of the cell cycle is regulated 
by [CONTACT_798217] -Rb-hSWI/SNF and Rb -hSWI/SNF. Cell 2000; 101: 
79-89. 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
96 
 19. Koepp DM, Schaefer LK, Ye X et al. Phosphorylation -dependent ubiquitination of cyclin E 
by [CONTACT_798197]7 ubiquitin ligase. Science 2001; 294: [ADDRESS_1100923] and redundant functions of cyclin E1 and cyclin E2 in 
development and cancer. Cell Div 2010; 5: 2.  
21. Aleem E, Kiyokawa H, Kaldis P. Cdc2 -cyclin E complexes regulate the G1/S phase 
transition. Nat Cell Biol 2005; 7: [ADDRESS_1100924] cancer. Lancet 2005; 365: [ADDRESS_1100925] AM, Jones PM, Vena N et al. Cyclin E1 deregulation occurs early in secretory cell 
transformation to promote formation of fallopi[INVESTIGATOR_8916] -derived high -grade serous ovarian 
cancers. Cancer Res 2014; 74: 1141 -1152.  
25. Sehdev AS, Kurman RJ, Kuhn E, Shih Ie M. Serous tubal intraepi[INVESTIGATOR_798178] -grade serous carcinomas including Rsf -1 (HBXAP), 
cyclin E and fatty acid synthase. Mod Pathol 2010; 23: 844 -855. 
26. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the 
biolo gic properties of ovarian cancer cells. Oncogene 2004; 23: [ADDRESS_1100926] cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and  
inactivation of the pRb node. Oncogene 2002; 21: [ADDRESS_1100927] 
cancer. N Engl J Med 2002; 347: 1566 -1575.  
29. Pi[INVESTIGATOR_8324] D, Bachmayr -Heyda A, Auer K et al. Cyclin E1 (CCNE 1) as independent positive 
prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD 
consortium. Eur J Cancer 2014; 50: 99 -110. 
30. Santala S, Talvensaari -Mattila A, Soini Y, Santala M. Cyclin E Expression Correlates with 
Cancer-specific Survival in Endometrial Endometrioid Adenocarcinoma. Anticancer Res 2015; 
35: 3393 -3397.  
31. Cassia R, Moreno -Bueno G, Rodriguez -Perales S et al. Cyclin E gene (CCNE) amplification 
and hCDC4 mutations in endometrial carcinoma. J Pathol 2003; 201: [ADDRESS_1100928], Wang DS, Chen YQ et al. Meta -analysis for cyclin E in lung cancer survival. 
Clin Chim Acta 2012; 413: 663 -668. 
33. Zhou Z, Bandla S, Ye J et al. Cyclin E involved in early stage carcinogenesis of esophageal 
adenocarcinoma by [CONTACT_798218]. BMC 
Gastroenterol 2014; 14: 78.  
34. Alsina M, Landolfi S, Aura C et al. Cyclin E amplification/overexpression is associated with 
poor prognosis in gastric cancer. Ann Oncol 2015; 26: 438 -439. 
35. Geng Y, Lee  YM, Welcker M et al. Kinase -independent function of cyclin E. Mol Cell 
2007; 25: 127 -139. 
36. Bagheri -Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E 
overexpression shortens mitosis, leading to chromosome missegregation and cen trosome 
amplification. Cancer Res 2010; 70: 5074 -5084.  
37. Bagheri -Yarmand R, Nanos -Webb A, Biernacka A et al. Cyclin E deregulation impairs 
mitotic progression through premature activation of Cdc25C. Cancer Res 2010; 70: 5085 -5095.  
38. Beck H, Nahse -Kumpf  V, Larsen MS et al. Cyclin -dependent kinase suppression by [CONTACT_173345]1 
NCI Protocol #: [ZIP_CODE]  
Version Date:  2 June 2020  
97 
 kinase protects the genome through control of replication initiation and nucleotide consumption. 
Mol Cell Biol 2012; 32: 4226 -4236.  
39. Aarts M, Sharpe R, Garcia -Murillas I et al. Forced mito tic entry of S -phase cells as a 
therapeutic strategy induced by [CONTACT_798219]1. Cancer Discov 2012; 2: 524 -539. 
40. Mahajan K, Mahajan NP. WEE1 tyrosine kinase, a novel epi[INVESTIGATOR_798179]. Trends Genet 
2013; 29: 394 -402. 
41. Heijink AM, Blomen VA, Bis teau X et al. A haploid genetic screen identifies the G1/S 
regulatory machinery as a determinant of Wee1 inhibitor sensitivity. Proc Natl Acad Sci U S A 
2015; 112: [ADDRESS_1100929] Cancer. Am J Pathol 2016.  
43. Bauer TM, Jones SF, Greenlees C et al. A phase 1b, open -label, multi -center study to assess 
the safety, tolerability, pharmacokinetics and anti -tumor activity of AZD1775  monotherapy in 
patients with advanced solid tumors: expansion cohorts. J Clin Oncol 2016; 34.  
44. Wingate H, Puskas A, Duong M et al. Low molecular weight cyclin E is specific in breast 
cancer and is associated with mechanisms of tumor progression. Cell C ycle 2009; 8: 1062 -1068.  
45. Duong MT, Akli S, Wei C et al. LMW -E/CDK2 deregulates acinar morphogenesis, induces 
tumorigenesis, and associates with the activated b -Raf-ERK1/[ADDRESS_1100930] cancer 
patients. PLoS Genet 2012; 8: e1002538.  
46. Schelle ns JHM, Marabelle A, Zeigenfuss S et al. Pembrolizumab for previously treated 
advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE -158 
study. J Clin Oncol 35, 2017 (suppl; abstr 5514) 2017.  
47. Infection includes all 75 site s of infection under the INFECTIONS AND INFESTATIONS 
SOC. In.  
48. Acute kidney injury includes renal impairment and acute renal insufficiency. In.  
49. Rash may include rash, erythema, eczema, and rash maculo -papular. In.  
50. Peripheral neuropathy includes both peripheral motor neuropathy and peripheral sensory 
neuropathy. In.  
51. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228 -247. 
52. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single -arm 
clinical trials with multiple outcomes. Stat Med 1995; 14: 357 -379. 
53.   Do, K, Wilsker D, Ji J et al. Phase I study of single -agent AZD1775 (MK -1775), a Wee1 
kinase inhi bitor, in patients with refractory solid tumors. J Clin Oncol 2015; 33:[ADDRESS_1100931] Ope rating Proce dures (SO P)  
98 
 
 
 
APPENDIX A : PERFORMANCE STATUS  CRITERIA  
 
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able to 
carry on all pre -disease performance 
without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able to 
carry out work of a light or sedentary 
nature ( e.g., light housework, office 
work).  80 Normal activity with effort; some 
signs or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed <50% of the time.  Ambulatory 
and capable of all self -care, but 
unable to carry out any work 
activities.  Up and about more than 
50% of waking hours.  [ADDRESS_1100932] of his/her 
needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time.  Capable of 
only limited self -care, confined to bed 
or chair more than 50% of waking 
hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospi[INVESTIGATOR_373].  Death not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self -
care.  Totally confined to bed or chair.  [ADDRESS_1100933] Ope rating Proce dures (SO P)  
99 
 
 
 
APPENDIX  B: PATIENT DRUG INFORMATION HANDOUT AND WALLET CARD  
Information for Patients , Their Caregivers , and Non -Study Healthcare Team  on Possible 
Interactions with Other Drugs and Herbal Supplements   
 
The patient ____________________________ is enrolled on a clinical trial using the experimental study 
drug, AZD1775.  This clinical trial is sponsored by [CONTACT_29630].  This form is addressed 
to the patient, but includes important informat ion for others who care for this patient.  
 
These are the things that you as a healthcare provider  need to know:  
AZD177 5 interacts with certain specific enzyme(s) in your liver*  and certain transport proteins that help 
move drugs in and out of cells** . 
 
*The enzyme(s) in question is/are CYP3A4 , CYP3A, CYP2C19, CYP1A2 and AZD1775  is broken down 
by [CONTACT_097]3A4, CYP3A  and is affected by [CONTACT_360448]3A4. AZD1775 
is also a possible weak inhibitor of CYP2C19 and inhibits CYP3A4 and may increase levels of other drugs 
that are cleared by [CONTACT_36918]. AZD1775 induces CYP1A2 enzyme that may result in decreased level of 
other drugs that are cleared by [CONTACT_36918].  
 
 **The protein(s) in question is/are P-glycoprotein (P -gp), multi -drug and toxin extrusion proteins 
(MATE1 and MATE2K)  and breast cancer resistance protein (BCRP). AZD1775 requires P -gp to move 
out of cells and concomitant administration of strong P -gp inhibitors and inducers should be avoided. 
AZD1775 inhibits BCR P, MATE1 and MATE2K transporter s and has the possibility of inducing P -gp and 
that may affect the transport of other drugs that depend on these proteins to move out of cells. Use caution 
when taking substrates of these transporters, such as statins.  
 
To the patient: Take  this paper with you to your medical appointments and keep the attached 
information card in your wallet .   
AZD1775  may interact with other  drugs  which can cause side effects. For this reason, it is very important 
to tell your study doctors of any medicines you are taking before you  enroll onto this clinical trial .  It is 
also very important to tell your doctors if you stop taking any regular medicine s, or if you start taking a 
new medicine while you take part in this study.  When you talk abo ut your current medications with your 
doctor s, include medicine you buy without a prescription (over -the-counter remedy), or any herbal 
supplements such as St. John’s Wort.  It is helpful to bring your medication bottles or an updated 
medication list with you. 
 
Many health care providers  can write prescriptions.  You must tell all of your health care providers 
(doctors, physician assistants , nurse practitioners , pharmacists ) you are taking part in a clinical trial.  
 
These are the things that you and they need to know:  
 
AZD1775  must  be used very carefully with o ther medicines that use certain liver enzymes or transport 
proteins to be effective or to be cleared from your system or that may affect your heart’s electrica l activity .  
Before you enroll onto the clinical trial , your study doctor will work with your regular health care 
providers to review any medicines and herbal supplements  that are considered strong in ducers/inhibitors 
or substrates  of CYP3A4, CYP3A, CYP2C 19, CYP1A2 , P-gp, MATE1, MATE2K and BCRP  
 
• Please be very careful!  Over -the-counter drugs  (including herbal supplements)  may contain ingredients 
DCTD Standard Ope rating Proce dures (SO P)  
[ADDRESS_1100934] to determine if there could 
be any side effects.   
• Avoid ingesting grapefruit, grapefruit juice and Seville oranges while taking AZD1775.  
• You may need to be monitored more frequently if you are taking any drugs that have narrow therapeutic 
ranges.  
•  Your regular health care provider s hould check a frequently updated medical reference or call your study 
doctor before prescribing any new medic ine or discontinuing any medicine .  Your study doctor’s name [CONTACT_832]  
_____________________________________ and he or she can be contact[CONTACT_6811] 
_____________________________________.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  STUDY DRUG INFORMATION WALLET CARD   
You are enrolled on a clinical trial using the experimental study  
drug  AZD1775.   This clinical trial is sponsored by [CONTACT_6812].   
__________________ may interact with drugs that are processed by 
[CONTACT_6813], or use certain transport proteins in your body .  Because of 
this, it is very important to:  
➢ Tell your doctors if you stop taking any medicine s or if you start 
taking a ny new medicine s. 
➢ Tell all of your health care providers  (doctor s, physician assistant s, 
nurse practitioner s, or pharmacist s) that you are taking part in a 
clinical trial.  
➢ Check with your doctor or pharmacist whenever you need to use 
an over -the-counter medicine or herbal supplement.  
 
  
 AZD1775 interacts  with specific liver enzymes called CYP3A4, CYP3A, 
CYP2C19, CYP1A2, transport protein, P -gp, MATE1, MATE2K and 
BCRP  and must be used very carefully with other medicines that 
interact with these enzymes and  transporter proteins.   
➢ Before you enroll onto the clinical trial, your study doctor will 
work with your regular health care providers to review any 
medicines and herbal suppleme nts that are prohibited.  
➢ Before prescribing new medicines, your regular health care 
providers should go to a frequently -updated medical reference  for 
a list of drugs to avoid, or contact [CONTACT_6814].   
➢ Your study doctor’s name [CONTACT_832] _____________________________  
and can be contact[CONTACT_6811] _________________________________ .  
DCTD Standard Ope rating Proce dures (SO P)  
101 
 
 
 
APPENDIX C: MEDICATION DIARY  
Study Name: A Phase II Study of AZD1775, a WEE1 Inhibitor, in Patients with CCNE1 Amplification.  
 
 
CTEP Study ID: [ZIP_CODE]  
 
Patient Initials:  ______________________________  
 
Patient Identification Number:  ______________________________  
 
 
Instructions to the patient:  
 
PLEASE  complete and  return this dosing diary along with  any unused AZD1775 and the 
container(s).  You will receive a new dosing diary for each treatment cycle.  Thank you for your 
participation in the very  important study!  
 
You will take: AZD1775  
 
Each time you take the AZD1775 study medication, your dose is _________ mg and is made u p of:            
 _____ 100mg capsules               
                              
              _____ 25mg capsules               
  
How to store your AZD1775 study medication  
The AZD1775 study  medication must be stored at room temperature (below 30ºC/86ºF) at all times.  
Please read the medication label for additional storage instructions.  
 
How to take your AZD1775 study medication  
• The AZD1775 study medication dose indicated above is to be take n once daily for five  (5) 
consecutive days at the start of Week 1 (Days 1, 2, 3 , 4 and 5 ) and Week 2 (Days 8, 9 , 10, 11 and 
12) of each cycle.   
• Each dose is taken orally (by [CONTACT_1966]) 2 hours before or 2 hours after food and at approximately the 
same time ea ch morning or evening.  
• You will take 1 0 doses in each cycle of 21 days.  
 
If you miss the daily dose according to the schedule ,  
• the dose should be taken as soon as possible, but not more than 12 hours after the missed dose was 
scheduled.  
• If greater than 12 hours, the missed dose should be skipped and you should take the next dose when 
scheduled.  
 
How to fill -in your AZD1775 dosing diary  
It is very important that you complete this dosing diary as accurately as possible and bring it completed 
along with all  remaining study medication (used and unused containers) to your next clinic visit.  
 
Please fill -in this dosing diary each day that you are scheduled to take study medication.   
DCTD Standard Ope rating Proce dures (SO P)  
[ADDRESS_1100935] time you took your study medication  and 
how many capsules taken. (  number of  100mg and/or number of  25mg)  
 
It is important that you do not miss any of your study medication, but if you do please provide a reason in 
the Comments box along with any other comments you would like the doctor to know.  
 
Cycle number: _________  
 
Start date: _________  
 
Patient Si gnature: _____________________________________  
  
DCTD Standard Ope rating Proce dures (SO P)  
103 
 
 
 
D
A
Y Date  
Time 
capsules 
taken  Number of 
capsules 
taken  Use the space below to make notes 
about things you would like to tell the 
doctor (including unusual symptoms 
you experience, other medicine you 
have taken and anything else you think 
would be of interest.)  Month     Day   Year  
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
15       
16       
17       
18       
19       
20       
21       
 
 
 
 
 
 
Title:   Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 1 of  11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/[ADDRESS_1100936] Ope rating Proce dures (SO P)  
104 
 
 
 
 
Laboratory of Human Toxicology &  Pharmacology Applied/Developmental  
Research Directorate, Leidos Biomedical Research,  Inc. 
Frederick National Laboratory for Cancer  Research  
 
Technical  Reviewer:  Yvonne A.  Evrard   Date:     
 
NCTVL  Reviewer:  Jiupi[INVESTIGATOR_798180]:     
 
IQC Approval:  Katherine V.  Ferry -Galow   Date:     
 
LHTP Approval:  Ralph E.  Parchment   Date:  
 
DCTD OD  Approval:  Joseph E.  Tomaszewski   Date:  
 
Change History  
 
Revision  Approval  Date  Description  Originator  Approval  
F 2/11/[ADDRESS_1100937] shippi[INVESTIGATOR_798181].  KFG  REP 
 
 
E  
 
7/3/2013  Updated tube -type to 1.5 -mL conical bottom  
screw  cap tubes to allow for broader use in 
DCTD  assays  and minimize the need to 
transfer biopsies  during  sample extraction 
steps. Decreased maximum  time from biopsy 
collection to freezing to 2  minutes.   
 
YAE   
 
REP 
 
D  
1/8/[ADDRESS_1100938] total time 
elapsed  from  biopsy collection to  freezing.   
YAE,  MM  
JJ 
C 12/29/2010  Update sample snap freeze to dry ice/ethanol 
bath or liquid  nitrogen.  YAE  JJ 
B 7/24/2009  Updated SOP format and prepared for 
publication  to the DCTD Biomarkers Web  site YAE  JJ 
A 10/13/2006  Revision with New Shippi[INVESTIGATOR_798182] 
-- 
 
 
  8/25/2006  New  Document  YZ JJ 
 
Please check for revision status of the SOP  at 
http://dctd.cancer.gov/ResearchResources/ResearchResources -biomarkers.htm  
and be sure to use the current  version.  
          
        
  
  
    
    
   
DCTD Standard Ope rating Proce dures (SO P)  
105 
 
 
 
Title:  Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 2 of  11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/2015  
 
 
TABLE OF  CONTENTS  
1.0 PURPOSE  ................................ ................................ ................................ ............................ 3 
2.0 SCOPE.  ................................ ................................ ................................ ................................ 3 
3.0 ABBREVIATIONS  ................................ ................................ ................................ ............. 3 
4.0 INTRODUCTION  ................................ ................................ ................................ ............... 3 
5.0 ROLES AND  RESPONSIBILITIES  ................................ ................................ ................... 3 
6.0 MATERIALS AND EQUIPMENT  REQUIRED  ................................ ................................ 4 
7.0 OPERATING  PROCEDURES  ................................ ................................ ............................ 5 
8.0 SHIP TO FNLCR FOR ANALYSIS  (OPTIONAL) ................................ ............................ 7 
APPENDIX 1: BATCH  RECORD  ................................ ................................ ................................ ..9 
APPENDIX 2: PD SAMPLE SHIPPI[INVESTIGATOR_798155]  ................................ ................................ .[ADDRESS_1100939] Ope rating Proce dures (SO P)  
106 
 
 
 
Title:  Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 3 of  11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/2015  
2.17 1.0 PURPOSE  
Standardize the method for collecting and handling frozen needle tumor biopsies to enable specimen  use 
for measurement of pharmacodynamic (PD) markers following treatment with anticancer  agents.  
2.18 2.0 SCOPE  
This procedure applies to all personnel involved in the collection and handling of frozen needle  tumor 
biopsies for use in PD marker assays during clinical trials. The goal of this SOP and associated training  is 
to ensure consistency in tumor needle biopsy collection and handling between clinical  sites.  
2.19 3.0 ABBREVIATIONS  
DCTD  = Division of Cancer Treatment and  Diagnosis  
ELISA  = Enzyme -Linked ImmunoSorbent  Assay  
FNLCR  = Frederick National Laboratory for Cancer  Research  
ID = Identification /  Identifier  
IQC = Internal Quality  Control  
LHTP  = Laboratory of Human Toxicology and  Pharmacology  
NCTVL  = National Clinical Target Validation  Laboratory  
PADIS  = Pharmacodynamics Assay Development & Implementation  Section  
PD = Pharmacodynamic  
SOP = Standard Operating  Procedure  
2.20 4.0 INTRODUCTION  
Specimen handling, shippi[INVESTIGATOR_007], and storage procedures (pre -analytical variables) can have a  significant 
impact on the reliability of biomarker measurements in the laboratory. Following detailed steps  for 
sample collection and handling procedures and recording any deviations from this procedure  allows 
retrospective  identification  of artifactual  changes  in biomarker  readout  and increases  the reliability  of the 
data and validity of the analytical  results.  
5.0 ROLES AND  RESPONSIBILITIES  
Laboratory  Director/Supervisor  The Laboratory Director/Supervisor, directs laboratory  operations,  
supervis es technical personnel and reporting of findings, and  is 
responsible for the proper performance of all laboratory  procedures. 
Oversees the personnel who follow the SOPs in the laboratory and  is 
responsible for ensuring the personnel are certified and have  sufficient 
experience to handle clinical  samples.  
Certified Assay Operator and/or PK/PD Support Lab  Personnel  
A Certified Assay Operator and/or PK/PD Support Lab personnel  may 
be a Laboratory Technician/ Technologist, Research Associate,  or 
Laboratory  Scientist who has been certified through DCTD training  on 
this SOP. Work under the guidance of the  Laboratory 
Director/Supervisor. This person performs laboratory procedures  and 
examinations in accordance with the current SOP(s), as well as  any 
other procedures conducted by a laboratory, including  maintaining 
equipment and records and performing quality assurance  activities 
related to  performance.  
DCTD Standard Ope rating Proce dures (SO P)  
107 
 
 
 
Title:  Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 4 of 11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/2015  
 
5.1 It is the responsibility of the Laboratory Director/Supervisor to ensure that all personnel  have 
documented training and qualification on this SOP prior to the actual handling and processing  of 
samples from clinical trial patients. The Laboratory Director/Supervisor is responsible  for 
ensuring the Certified Assay Operator running the SOP has sufficient experience to handle  and 
analyze clinical  samples.  
5.2 It is the responsibility of th e Certified Assay Operator and/or PK/PD Support Lab pers onnel  to 
confirm scheduled specimen collection time po ints, pre -print all labels and data collection  sheets 
in advance, check documentation for accuracy, and verify that the required collection  tubes,  
supplies, and equipment are available for successful collection and handling of biopsy  samples.  
5.3 The Certified Assay Operator and/or PK/PD Support Lab personnel responsible for  conducting 
the specimen collection and handling procedures are to follow this SOP and complete the  required 
tasks  and  associated  documentation.   The  Batch  Record  ( Appendix  1 )  must  be  completed            
in real-time for each experimental run, with each page dated and initialed , and placed with  the 
clinical sample  information.  
5.4 The responsible personnel are to check the DCTD Bio markers Web  site 
(http://dctd.cancer.gov/ResearchResources/ResearchResources -biomarkers.htm ) to verify that  the 
latest SOP version is being  followed.  
6.0 MATERIALS AND EQUIPMENT  REQUIRED  
6.1 Stop watch, total time in minutes and seconds  required  
6.2 1.5-mL Sarstedt o -ring screw cap, conical bottomed tubes (Sarstedt, Cat#:  72.703.416)  
6.3 Disposable, fine-tipped tweezers (e.g., VWR, Cat#: [ZIP_CODE] -010). Tweezer tips need to easily  fit 
to bottom of a 1.[ADDRESS_1100940] freezer boxes (e.g., Fisher Scientific, Cat#:  12-565-182) 
6.6 Thermofla sk cooler or polystyrene foam  container  
6.7 Ice bucket  
6.8 Liquid nitrogen or dry ice/etha nol bath 
6.9 Wet ice 
6.10 -80°C freezer (or  lower)  
DCTD Standard Ope rating Proce dures (SO P)  
108 
 
 
 
Title:  Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 5 of  11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/[ADDRESS_1100941] the name [CONTACT_798223]/or PK/PD  Support 
Lab personnel performing the SOP, the facility/clinic collecting the specimens,  the 
Patient/Sample ID, and the clinical protocol number in the Batch Record ( Appendix  1). 
o The Batch Record for this SOP is sufficient for collection of a single patient’s  biopsy 
samples; if collecting biopsy samples for more than one patient, prepare a separ ate Batch 
Record for each  patient.  
7.2 Prepare enough pre -printed specimen labels for each whole or halved biopsy sample to  be 
collected and frozen as defined in the Pharmacodyn amic/Correlative Study section of the  Clinical 
Protocol; be sure to coordinate with the clinical center if they prepare the labels for  sample 
collection.  
If two passes are collected from one tumor, the labels would be identical except that the  specimen 
ID would be followed by a lower case  a/b to designate pass number.  The specimen ID  includes 
the CTEP protocol number followed by a unique patient identifier and a specimen series  ID. 
NCI tumor biopsy specimen IDs for PD sampling are series 500 with consecutive  numbers 
identifying the collection time point as defined in the Clinical Protocol.  Sample pre -printed  label:  
 
 
7.[ADDRESS_1100942] (Appendix 1), and the last will be given to  the research nurse  to 
place into the patient record  sheet.  
7.[ADDRESS_1100943] relevant clinical  information, 
and ensure rapid transport of specimens to the laboratory for placement at -80ºC  (or 
lower) after  collection.  
7.4.2 Bring all necessary la b supplies including: disposable tweezers, a minimum of  two 
1.5-mL Sarstedt tubes (one for each whole biopsy core) pre -cooled on liquid nitrogen  or 
dry ice/ethanol in an insulated bucket, and one pre -printed specimen label to give to  the 
research nurse for the patient  record.  
Note : Pre-chill additional 1.[ADDRESS_1100944] Ope rating Proce dures (SO P)  
109 
 
 
 
Title:   Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 6 of  11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/2015  
 
7.4.3 The total time elapsed betwe en biopsy collection and placement into the pre -chilled  tube 
is of key importance to biomarker analysis; biopsies should be frozen within 2min  of 
collection. The interventional radiologist will eject the biopsy onto a sterile slide  (for 
optimal analyte recovery the slide should be pre -chilled). Start a stop watch (or note  the 
time) at this point (Appendix 1, Section 1) and immediately walk the slide to the  sample 
preparation  table.  
Note: The preferred method of collection, when whole  biopsies are collected, is for  the 
interventional radiologist to eject the biopsy directly into the pre -chilled tube (next  step). 
This minimizes the time between collection and fixation of  analytes.  
7.4.4 Indicate if a full or halved biopsy, as defined in the Pharmacodynamic/Correlati ve Study 
section of the Clinical Protocol, is prepared in the Batch Record (Appendix 1, Section  1). 
[IP_ADDRESS]  For whole biopsies : Uncap an empty, prechilled 1.5 -mL Sarstedt tube  and 
using disposable tweezers, pi[INVESTIGATOR_798183] d needle biopsy with  the 
tweezers at one end, and touch the opposite end of the biopsy to the  inner 
surface of the prechilled 1.5 -mL Sarstedt tube. This should attach the tissue  to 
the tube, allowing it to be dropped into the tube while releasing the tissue  from 
the tweezers without sticking. Dispose of the tweezers in the  appropriate 
biohazardous waste  container(s).  
[IP_ADDRESS]  For halved biopsie s: Use 1 -2 disposable tweezers and cut/shear the biopsy  in 
half cross -wise while it is on the slide (do not pull or str etch the  biopsy 
longitudinally). Use the tweezers to transfer the halved biopsies  to sterile  pre- 
chilled tubes as indicated  above.  
7.4.5 Immediately snap freeze the biopsy by [CONTACT_798220] a  dry 
ice/ethanol  bath.  
7.4.[ADDRESS_1100945] (Appendix 1,  
Section 1).  
7.[ADDRESS_1100946] (Appendix 1, Section 2.). Some information may not  be 
available until a later time from the clinical  staff.  
During first-in-human PD sample collection studies, information such as type of anesthesia  and 
time-lag between biopsy needle withdrawal and sample freezing need to be tracked in order  to 
determine the optimal sample collection procedure for the clinical  community.  
7.6 Return to the sample processing laboratory and transfer the frozen biopsy specime n(s) to  -80°C 
(or lower) for storage until shipment to the PD processing laboratory. Record the date and  time 
specimens are placed at -80ºC (or lower; Appendix 1, Section  3). 
7.[ADDRESS_1100947] (Appendix 1, Section  5). 
7.8 The Labor atory Director/Supervisor should review the Batch Record and sign to affirm the  data 
contained within are correct ( Appendix 1, Section  6). 
DCTD Standard Ope rating Proce dures (SO P)  
110 
 
 
 
Title:  Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 7 of  11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/2015  
 
8.0 SHIP TO FNLCR FOR ANALYSIS  (OPTIONAL)  
If shippi[INVESTIGATOR_86286] a location other than FNLCR, use the following steps as a  guide.  
8.[ADDRESS_1100948] return shipment labels send an e -mail to [EMAIL_980]  and 
state “ Protocol Name [CONTACT_798224]” in the subject line. Specify  the 
address to which the shipment labels should be provided and the number of  shipment 
labels requested. Shipment labels will be provided within 6 business  days.  
8.2 Once a tumor biopsy has been collected from a patient and placed at -80ºC (or lower),  FNLCR 
PD Specimen Central Receiving should be notified that the specimens are ready for  shipment.  
8.3 Send an  e-mail to FNLCR  PD Specimen  Central  Receiving  ([EMAIL_980] ) to 
advise that biopsy samples are being prepared for shipment.  State “ Protocol Name  [CONTACT_243610]” in the subject line. Request a confirmation e -mail that  personnel 
will be available on the expected delivery date and time. Personnel are generally available  to 
receive frozen shipments Tuesday through Friday, exclusive of government holidays. If  needed, 
FNLCR PD Central Receiving can be contact[CONTACT_243592]  [PHONE_5112].  
8.[ADDRESS_1100949] 
containing pertinent sample information and FN LCR PD Specimen Central Receiving  shippi[INVESTIGATOR_200915].  
Attention: Dan  Danner 
NCI-F/FNLCR  
[ADDRESS_1100950], Building  1073 Fort  Detrick  
Frederick, MD  [ZIP_CODE]  
Phone:  [PHONE_932]  
8.[ADDRESS_1100951] freezer box and then in  a 
shippi[INVESTIGATOR_798184] -20°C for at  least 
72 h. All weekly processing specimens are recommended to ship out via FedEx on  the 
following Monday afternoon for delivery by 10 AM Tuesday (FedEx First  Overnight).  
8.6.[ADDRESS_1100952] 
inside the shippi[INVESTIGATOR_798185].  
8.6.3 Seal the box and print and attach the shippi[INVESTIGATOR_798186] t he shippi[INVESTIGATOR_34919]; be sure the container is labeled as containing biohazardous  specimens.  
8.6.[ADDRESS_1100953] (Appe ndix 1, Section  4). 
 
DCTD Standard Ope rating Proce dures (SO P)  
111 
 
 
 
Title:  Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 8 of  11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/2015  
 
8.6.5 E-mail FNLCR PD Specimen Central Receiving ( [EMAIL_980] ) a 
shipment notification. State “ Protocol Name [CONTACT_798225]” in the subject  line 
and reference the tracking number in the  e-mail.  
8.6.6 Once specimens arrive at the receiving laboratory, they should be immediately placed at  - 
80ºC (or lower) pending delivery to the processing laboratory for protein  extraction.  
 
DCTD Standard Ope rating Proce dures (SO P)  
[ADDRESS_1100954]  INITIALS:   DATE:     
Title:  Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 9 of  11 
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/2015  
APPENDIX 1: BATCH  RECORD  
A separate Batch Record should be started for each patient  sample . 
Note : A pre-dose and post-dose sample  from the same  patient  would have 
the same Patient ID, but different Specimen ID  numbers.  
 
Note : Record  times  using  military  time (24-h designation);  for 
example,  specify 16:15 to indicate 4:15  PM. 
 
Certified Assay  Operator:      
Certification  Number:       
 ☐ Check here if PK/PD Support Lab  Personnel  
 
Facility/Clinic Collecting  Specimens:       
Clinical Protocol  Number:             
Patient  ID:     
 
1. Biopsy Collection  
 
1st Pass   2nd 
Pass   3rd 
Pass   4th 
Pas s 
Specimen  ID     
Biopsy size prepared for PD  or 
histological  analysis:  ☐ Full 
☐ Halved  ☐ Full 
☐ Halved  ☐ Full 
☐ Halved  ☐ Full 
☐ Halved  
Required:  
Time elapsed from collection  to 
placement in  tube  
 
min  
 
sec  
 
min  
 
sec  
 
min  
 
sec  
 
min  
 
sec 
Time biopsy collected  (opt)  : : : : 
Time biopsy placed in  tube 
(opt)   
:  
:  
:  
: 
 
 
 
 
 
 
 
  
 
 
 
Place  
PD Speci men 
Label  Here 
DCTD Standard Ope rating Proce dures (SO P)  
[ADDRESS_1100955]  INITIALS:   DATE:    BATCH RECORD   Title:  Appendix D: Tumor Frozen Needle Biopsy Specimen Collection and  Handling  Page 10 of 11  
Doc.  #: SOP340507  Revision:  F Effective  Date:  2/11/2015  
 
2. Biopsy Procedure  Details  
 
Specimen  ID  
Time local anesthesia  administered  : 
Dose of local  anesthetic  mg 
Name [CONTACT_798226] (from Research  Nurse)   
Time of skin  incision  : 
Needle Type (e.g.,  Temno)   
Needle  diameter  gauge  
Needle  Length  cm 
Time guide needle  introduced  : 
Time guide needle placement  confirmed  : 
Time biopsy needle  introduced  : 
 
3. Biopsy Storage  
 
Date/time biopsy specimen(s) placed  at 
-80°C (or  lower)   / /   :   ºC   
 
4. Shippi[INVESTIGATOR_798187] (optional)  
 
Date and time samples  shipped     :    
Tracking  information  
**Attach copy of Shippi[INVESTIGATOR_404107]  
5. Notes, including any deviations from the  SOP:  
 
 
 
 
 
 
 
 
6. Laboratory Director/Supervisor Review of Batch  Record  
Laboratory  Director/Supervisor:  (PRINT)  
  (SIGN)  
Date:   / /   
DCTD Standard Ope rating Proce dures (SO P)  
114  
 
 
APPENDIX 2: PD SAMPLE SHIPPI[INVESTIGATOR_798188]: Appendix D: T umor Frozen  Needle Biopsy Spec imen Collecti on and Handling Page 11/11  
Doc. #: SOP340507  Revision: F Effective Date: 2/11/2015  
 
From: 
 
 
 
 
 
Phone: 
E-mail:  
PD Sample 
Ship pi[INVESTIGATOR_798189]/Specimen ID Clinical Protocol Descr iption Time Point Scheduled Collection Date  
 Example 1234-1023-500 12-C-0000 Full biopsy Pre-dose D1 06/06/2018  
 Example 1234-1023-501 12-C-0000 Half biopsy Cycle 1, D8 06/06/2018  
☐  1      
☐  2      
☐  3      
☐  4      
☐  5      
☐  6      
☐  7      
☐  8      
☐  9      
☐  10      
 